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GLT1  Glutamate transporter (EAAT2) 
GSH  Glutathione 
GTRAP Glutamate transporter associated protein 
mGLUR Metabotropic glutamate receptors 
MSO  Methionine sulfoximine 
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Minireview 
 
In addition to being an amino acid and a component of proteins, glutamate is the main 
excitatory neurotransmitter in the central nervous system (CNS) (for review see: Fonnum, 
1984; Ottersen and Storm-Mathisen, 1984; Danbolt, 2001). Glutamate is involved in most 
aspects of normal brain function including cognition, memory and learning. Brain tissue 
contains large amounts of glutamate, around 5-15 mmol per kg depending on the region 
(Schousboe, 1981). The extracellular concentrations are kept low and are in the order of a 
few micromolar (Hamberger et al., 1983), or may be even lower (Herman and Jahr, 
2007). The highest glutamate concentrations are found intracellularly in glia cells, nerve 
terminals and synaptic vesicles (in increasing order) (Ottersen et al., 1992). It is 
suggested a concentration of more than 60 mM inside synaptic vesicles (Shupliakov et 
al., 1992). The concentration in cytosol is not known, but assumed to be in the low 
millimolar range implying that the concentration gradient across the plasma membrane is 
several thousand fold. 
 
 
 
 
 
 
 
 
 
Figure 1: The concentration gradients across the plasma membranes are great. The extracellular 
glutamate concentration is around 1 M, inside nerve terminals it is around 10 mM and 100 mM 
in synaptic vesicles (for references see: Danbolt, 2001). 
 
When glutamate has been released into the extracellular space, it binds to glutamate 
receptors on neuronal and glial cell membranes to exert its signaling role. The glutamate 
receptors are divided into three families (for review see: Kristensen et al., 2006). One 
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family is the metabotropic receptors which are coupled to G-proteins (mGluR1-8). 
Activation of these receptors leads to changes in inositol phosphate or cyclic nucleotide 
metabolism. The two other families are ionotropic receptors which mean that they are 
glutamate gated ion channels that conduct Na+ or Ca2+. They are named after the 
glutamate analogues that activate them. One of them is NMDA (N-methyl-D-aspartate) 
receptors which has high affinity for glutamate and are slowly inactivating. The last 
family is AMPA (-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) or kainate 
receptors according to their preference for AMPA or kainate. AMPA/kainate receptors 
are rapidly inactivating and have low affinity for glutamate.  
 Because glutamate modulates fundamental neurological processes and because 
glutamate only can act on the glutamate receptors from the outside, the extracellular 
concentrations must be tightly controlled. Both too much and too little receptor 
stimulation can be harmful l(Danbolt, 2001). There is no enzyme extracellularly that can 
metabolize glutamate, so the glutamate must be removed by cellular uptake (for review 
see: Danbolt, 2001). Although simple diffusion may be important for the reduction of 
glutamate in the synaptic cleft in the submillisecond timescale (Clements, 1996), 
diffusion can only cause glutamate redistribution. It cannot cause real removal from the 
extracellular fluid. The only mechanism for net removal is cellular uptake mediated by 
the glutamate transporters located in both neurons and astroglia (for review see: Danbolt, 
2001).  
 The close proximity of astrocytes to synapses points towards glia as a part of the 
synaptic functional unit.  The term “the tripartite synapse” has been introduced in 
recognition of the contribution of astrocytes to synaptic function (Volterra et al., 2002). 
In addition to clearance of neurotransmitters, it has been proposed that astrocytes can 
have neuron–like activities like releasing glutamate (Bezzi and Volterra, 2001). This, 
however, is still debated. For instance, a recent transcriptome database does not give 
support to the notion that astrocytes express the proteins involved in vesicular glutamate 
release (Cahoy et al., 2008) and it remains to be shown if glutamate containing vesicles 
exists in astrocytes. 
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Glutamate transporters  
Glutamate transporters are also called “sodium and potassium coupled glutamate 
transporters” or “excitatory amino acid transporters” (“EAATs”).  The term “sodium 
dependent high-affinity transporters” have earlier been in use, but because the affinity not 
is particular high (Km varying between 1-100 M depending on the subtype and assay 
method) and because the transporters also depend on potassium, this term is no longer in 
common use (Danbolt, 2001). Five distinct glutamate transporter subtypes have been 
cloned from animal and human tissue and have been assigned to the solute carrier family 
(slc) number 1: GLAST (EAAT1; slc1a3; Storck et al., 1992), GLT1 (EAAT2; slc1a2; 
Pines et al., 1992), EAAC1 (EAAT3; slc1a1; Kanai and Hediger, 1992), EAAT4 (slc1a6; 
Fairman et al., 1995), and EAAT5 (slc1a7; Arriza et al., 1997). In addition several splice-
variants of the various EAATs have been reported (Utsunomiya-Tate et al., 1997; Meyer 
et al., 1998a; Münch et al., 1998; Meyer et al., 1999; Huggett et al., 2000; Rauen et al., 
2004; Rozyczka and Engele, 2005). Two transporters for neutral amino acids (alanine 
serine cysteine transporter; ASCT1 and 2; gene slc1a4 and 5) have also been assigned to 
this family. There are also other transporters capable of transporting glutamate. For 
instance, in mitochondria there are “mitochondrial glutamate transporters” (for review 
see: Sluse, 1996) and in synaptic vesicles (Varoqui et al., 2002; Chaudhry et al., 2008) 
there are “vesicular glutamate transporters” (VGLUT1-3; slc17a6-8). In the plasma 
membrane there are transporters for neutral amino acids (e.g. ASCT2; slc1a5) and 
dicarboxylates (e.g.NAC3; gene slc13a5) that can transport glutamate with low affinity. 
In addition there is a glutamate-cystine exchanger (xCT; slc7a11) that exchange 
extracellular cystine with intracellular glutamate (Sontheimer, 2003; Sato et al., 2005). 
 
Transport mechanism and stoichiometry  
Glutamate transporters use the electrochemical gradients of Na+, K+ and H+ to transport 
glutamate into the cells (Kanner and Sharon, 1978). In that way they are secondary active 
transporters because the gradients for Na+ and K+ are maintained by the Na+/ K+-ATPase 
which requires ATP to work. The transport is electrogenic because more positive charge 
moves in than out in each transport cycle. The transport is therefore stimulated by the 
negative membrane potential. The glutamate transporters can work in both directions and 
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are described as shuttles that transport either glutamate, Na+ and H+ or K+. When 
glutamate/ Na+/ H+  is transported into the cell, either K+ or glutamate/ Na+/ H+  have to 
be transported out before starting a new transport cycle. Na+ is required for glutamate 
binding and K+ is required for net transport. In the absence of K+, the transporters are 
locked in exchange mode and can only exchange external substrate with internal substrate 
(Danbolt, 2001). It is important to note that failed cycles occur in between completed 
(net) transport cycles (see Volterra et al., 1996). Exchange can  be considered incomplete 
or as failed transport cycles. The stochiometry (the fixed number of ions involved in the 
transport) of the transporters have been determined to be 1 glutamate, 3 Na+, 1 H+, 1 K+ 
for EAAT1-3 (Zerangue and Kavanaugh, 1996a: Levy et al., 1998; Owe et al., 2006). 
This is an important parameter as it determines the concentrative capacity of the 
transporters, their energy consumption and the sensitivity to changes in ion gradients. In 
addition to the stoichometric transport the transporters also function as ion channels (in 
particular EAAT4 and 5, but almost non-existing in GLT1. For review see Seal and 
Amara, 1999) and as water channels (at least in the case of EAAT1) (MacAulay et al., 
2001).  
 
 
 
Figure 2:  The stoichiometric transport of glutamate transporters. The transporters operate as 
shuttles that catalyze the stoichiometric transport of 1 glutamate, 3 sodium and 1 hydrogen ion 
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inwards in exchange with 1 potassium ion. In addition 400 water molecules are transported to 
the inside and the transporters can operate as ion channels. 
 
Substrate selectivity 
The glutamate transporter’s specificity for glutamate is not absolute, because they can 
transport L-glutamate, D-aspartate, L-aspartate and L-cysteate with nearly the same 
affinity. In addition several analogs have been made. The glutamate molecule is very 
flexible and can have many different conformations. This explains how transporters, 
receptors and enzymes can bind glutamate despite having very different binding sites. 
This is what medicinal chemists exploit when they construct new molecules mimicking 
different glutamate conformations. Transportable glutamate analogs with high affinity 
include threo--hydroxyaspartate (THA), L-trans-pyrrolidine-2,4-dicarboxylic acid, L-
serine-O-sulfate (L-SOS) and (2S,1’S,2’R)-2-(2-carboxycyclopropyl)glycine (CCG-III). 
There are also some non-transportable analogs, blockers, like dihydrokainic acid (DHK) 
and threo--benzyloxyaspartate (TBOA) derivatives (for review see: Bridges et al., 1999; 
Shimamoto and Shigeri, 2006). 
 
Glutamate transporter structure 
EAAT1-5 are glycoproteins consisting of between 500 and 600 amino acids. Their 
molecular masses are in the range of 60-75 kDa. They share 50-60 % amino acid 
sequence. Parts of the sequence are highly conserved between the EAATs, suggesting 
these parts play an important role. For instance, residues 396-400 (GLT1 nomenclature) 
are shown to be important for transport activity and to participate in sodium binding 
(Zarbiv et al., 1998; Zhang et al., 1998). And the residues 403-404 appear to be involved 
in potassium binding (Kavanaugh et al., 1997). Based on the crystal structure of a 
bacterial glutamate transporter homologue (Yernool et al., 2004), the transporters are 
predicted to have 8 transmembrane domains with intracellular amino- and carboxy-
terminals. It is bowl-shaped with a large aqueous basin which makes glutamate easily 
reach binding sites halfway into the membrane, this architecture is well suited for rapid 
binding of glutamate in synapses. It has a triangular shape with sides of 80 Å. They most 
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likely both exist and work as trimers (Haugeto et al., 1996; Koch and Larsson, 2005; 
Grewer and Rauen, 2005). 
 
Localizations and quantifications 
The five different EAATs are found in different amounts in different areas of the brain. 
Quantification in absolute terms is required to know which glutamate transporter 
subtypes are dominating in different brain regions. The absolute amounts are also needed 
to determine their capacity in mathematical models (e.g. Rusakov and Kullmann, 1998) 
and to answer whether there is enough of the protein for its proposed role. 
Immunohistochemical studies have suggested that GLAST and GLT1 are both expressed 
in the plasma membranes of astrocytes facing neuropil (Lehre et al., 1995; Chaudhry et 
al., 1995; Lehre and Danbolt, 1998; Furness and Lehre, 1997; Furuta et al., 1997a; Furuta 
et al., 1997b; Furuta et al., 1997a Shibata et al., 1997). It is also shown that GLAST and 
GLT1 coexist in the same astrocytic membrane (Lehre et al., 1995; Haugeto et al., 1996), 
but as different homooloigomeric complexes (Haugeto et al., 1996). GLAST is the major 
glutamate transporter in the cerebellum (Lehre et al., 1995), the inner ear (Furness and 
Lehre, 1997; Takumi et al., 1997), the circumvenrtricular organs Berger and Hediger, 
2000) and in the retina (Derouiche and Rauen, 1995), while GLT1 is the quantitative 
dominating glutamate transporter in the forebrain: about 1% of total brain protein is 
GLT1 (Danbolt et al., 1992; Lehre and Danbolt, 1998). GLAST and GLT1 are expressed 
at low levels at birth, but increases dramatically during development (Ullensvang et al., 
1997). The highest increase is during synaptogenesis (P14-P28). The concentrations of 
GLAST and GLT1 are very high: 15 000 and 23 000 molecules per m3 in the stratum 
radiatum of hippocampus and molecular layer of cerebellum, respectively (see also Table 
1 below). By employing a stereological method to estimate the cell membrane area 
containing these transporters, it was possible to calculate the density of transporters in the 
membranes (Lehre and Danbolt, 1998).  
   EAAT4 is mainly found in the Purkinje cell spines and dendrites in the 
cerebellar molecular layer (Dehnes et al., 1998). It is expressed at low levels in the 
forebrain. In the cerebellum the amount of EAAT4 is 0.2 mg/g tissue giving a density of 
1800 molecules per m2 spine membrane. 
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 EAAT5 is only found expressed in retina (Arriza et al., 1997), where it is 
localized in Müller cells and neurons (Eliasof et al., 1998). It seems that the associated 
chloride conductance is more important for EAAT5’s physiological role than the 
transport function (Veruki et al., 2006; for review see Wadiche and von Gersdorff, 2006). 
 EAAC1 is a neuronal glutamate transporter (see paper IV included in this thesis). 
 
GLT1 splice variants 
The mRNA encoding GLT1 is large (11 kb; Pines et al., 1992) and has been found to 
have more than 30 splice variants; some of which translate into variant proteins 
(Utsunomiya-Tate et al., 1997; Meyer et al., 1998b; Münch et al., 1998; Meyer et al., 
1999; Rozyczka and Engele, 2005; Rauen et al., 2004). Alternatively splicing of both N- 
and C-terminal exist. The functional properties are not changed by altering the termini 
(Sullivan et al., 2004). There exist at least three different C-terminal GLT1-variants 
(Rauen et al., 2004). The first studies on GLT1 protein localization (Danbolt et al., 1992; 
Lehre et al., 1993; Levy et al., 1993; Chaudhry et al., 1995; Lehre et al., 1995) used 
antibodies recognizing all isoforms. Subsequent antibodies (Rothstein et al., 1994; 
Schmitt et al., 1996) raised to the extreme C-terminus of GLT1a gave a seemingly 
identical labeling pattern.  In contrast, the first reports on the distribution of GLT1b 
(protein and mRNA) in the brain were conflicting as some investigators detected it in 
neurons (Schmitt et al., 2002; Chen et al., 2002; Kugler and Schmitt, 2003; Reagan et al., 
2004), including nerve terminals (Chen et al., 2002), while others only observed 
astroglial expression of the protein (Reye et al., 2002; Sullivan et al., 2004). Chen and co-
workers later concluded that their anti-GLT1b antibodies were not specific (Chen et al., 
2004). Instead they found that antibodies to GLT1a labeled (in hippocampus CA1) a 
subset of axon terminals and spines in addition to astroglia. Berger and co-workers 
(2005) demonstrate that the probes used for detection of GLT1b mRNA have an 
unspecific component, and conclude that both isoforms are widely expressed in 
astrocytes and that GLT1a is the predominant neuronal isoform. The expression of 
GLT1a protein in terminals was confirmed in the hippocampus (Furness et al., 2008) and 
in the somatic sensory cortex (Melone et al., 2009). Four different GLT1 N-terminal 
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variants also exist (Utsunomiya-Tate et al., 1997; Rozyczka and Engele, 2005), although 
it is unknown which of N-terminal variants that are expressed in the CNS in vivo. 
 
Glutamate is recycled (the glutamate-glutamine cycle) 
From the described localization and quantification data above it follows that the majority 
of glutamate uptake is catalyzed by GLT1 which is mainly localized in glia (Paper V). In 
order to be recycled, this means that the glutamate must be further transported to get back 
to the nerve terminals. In glia glutamate is detoxified to glutamine by glutamine 
synthetase. Glutamine is transported out of the glia cell by glutamine transporters and 
taken up by nerve terminals by another glutamine transporter. Inside mitochondria of the 
nerve terminal glutamine is reconverted to glutamate by the neuron-specific phosphate 
activated glutaminase (PAG). The glutamate is then loaded into vesicles by vesicular 
glutamate transporters (VGLUTs) and ready for use again. 
 
 
 
Figure 3: Recycling of glutamate by the glutamate-glutamine cycle. Glutamate is released from 
the nerve terminal and taken up by glutamate transporters in the dendritic spine (I), the nerve 
terminal (VI) and in the glial cell (II). Inside the glial cell it is detoxified to glutamine by 
glutamine synthetase, released to the extracellular space by a glutamine transporter (III) and 
taken up in the neuron by another glutamine transporter (IV). (Reproduced from Danbolt 2001). 
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The importance of the glutamate-glutamine-cycle is discussed, but there are several 
evidences for its importance. Inhibition of glutamine synthetase by methionine 
sulfoximine (MSO) leads to a loss of synaptic activity in the retina and depletion of 
neuronal glutamate (Laake et al., 1995; Barnett and Pow, 2000). Inhibition of glutamine 
synthetase also inhibits epileptiform activity on hippocampal cultures (Bacci et al., 2002). 
Also the majority of the glutamate transporters are localized in the proximity of synapses 
and glutamine synthetase is exclusively a glial enzyme while PAG is neuronal. On the 
other hand, de novo synthesis of glutamate from glucose has considerable function 
because each glutamate molecule, on the average, only can be recycled 3-4 times before 
being oxidatively degraded by the Krebs cycle (Hertz et al., 1999). Glutamatergic 
neurons can also sustain glutamate release independent of glutamine by pyruvate 
carboxylation (Hassel and Bråthe, 2000), although it has earlier been reported that 
pyruvate carboxylase is an astrocytic enzyme (Yu et al., 1983).   
 
Uptake of glutamate into nerve terminals 
It seems bothersome to do this recycling through glial cells. The most efficient would be 
direct uptake of glutamate into the nerve terminals. On the other hand, the uptake is 
electrogenic contributing to depolarization, and this may be a reason why evolution has 
favored sharing the burden with astrocytes. This uptake has been a mystery. Several 
studies have shown that this uptake exists, but the protein responsible has unvaded 
detection (see comments to Paper V).  
 
Regulation 
Glutamate uptake can be regulated on virtually all levels: DNA transcription, mRNA 
splicing, protein synthesis, targeting, glutamate transport and associated ion channel 
activity (Danbolt, 2001). A number of substances and proteins have shown to affect 
uptake activity and expression of glutamate transporters. Interestingly, several regulatory 
mechanisms can have differential effect on different subtypes of glutamate transporters.  
 Dependence of neurons for glial glutamate transporter expression is also shown in 
vivo when GLAST and GLT1 levels are reduced in striatum after lesioning of afferent 
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glutamatergic nerve fibers (Levy et al., 1995; Ginsberg et al., 1995). When astrocytes are 
cultured in the presence of neurons they express both GLT1 and GLAST, while pure 
astroglial cultures only express GLAST (Gegelashvili et al., 1997a; Swanson et al., 
1997). Glutamate uptake is thought to be modulated by it’s substrate glutamate. When 
glutamate binds to glutamate receptors, it is thought that this may represent a feedback 
regulatory mechanism for glutamate uptake. Long-term treatment of astrocytes in culture 
with L-glutamate (0.1-3 mM) resulted in a dose-dependent increase in uptake activity 
(Gegelashvili et al., 1996). In addition glutamate uptake is modulated by fatty acids like 
arachidonic acid (Trotti et al., 1995; Zerangue et al., 1995; Dunlop et al., 1999), by 
phosphorylation (for review see Gonzalez and Robinson, 2004), by red-ox mechanisms 
(Volterra et al., 1994; Trotti et al., 1997), and by growth factors, cytokines and soluble 
factors (Gegelashvili et al., 1996; Gegelashvili et al., 1997b; Schlag et al., 1998). 
Glutamate transporters are kept in position and modulated by proteins connected to the 
cytoskeleton. Four such proteins have so far been characterized: Ajuba which binds 
GLT1 (Marie et al., 2002), GTRAP3-18 which binds EAAC1 (Lin et al., 2001), and 
GTRAP41 and GTRAP48 that binds EAAT4 (Jackson et al., 2001). Increased GTRAP3-
18 expression in cells reduces glutamate transport by lowering substrate affinity of 
EAAC1. This is also seen in another study where glutathione is decreased when 
GTRAP3-18 expression is increased, then GTRAP3-18 modulate EAAC1s uptake of 
cysteine which is necessary to make glutathione (Watabe et al., 2008). GTRAP3-18 
might act as an endogenous inhibitor of EAAC1. On the other side Ajuba is not found to 
alter glutamate transport mediated by GLT1, Ajuba's function with respect to glutamate 
transport is unclear. NMDA-receptor subunits also interact with EAAC1 to control 
surface expression, suggesting a close relationship between glutamate receptors and 
transporters (Waxman et al., 2007). In general, the machinery for EAAC1-trafficking 
seems to be more developed than for the other transporters. Which is logical since 
EAAC1 is expressed in both kidneys and intestine (Paper IV) where metabolic needs 
rapidly changes.  Further evidence of differential regulation of glutamate transporter 
subtype expression is seen during development (Ullensvang et al., 1997, Furuta et al., 
1997a). Rothstein et al. (2005) reported that -lactam antibiotics (e.g. ceftriaxone) 
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selectively elevate GLT1 expression. Ceftriaxone appeared to be cytoprotective both in 
vitro and in vivo in a mouse model of ALS (Rothstein et al., 2005). 
The importance of glutamate transporters 
As shown (Lehre and Danbolt, 1998) the concentration of the major glutamate 
transporters are very high, 15 000 and 23 000 molecules per m3 in the stratum radiatum 
of hippocampus and molecular layer of cerebellum, respectively. Whether the glutamate 
transporters manage to clear the synaptic released glutamate will depend on several 
factors. First, it depends on how much glutamate is released. One m3 contains about one 
glutamatergic nerve terminal (Woolley and McEwen, 1992). It is assumed that one 
vesicle is released at the time, and that each vesicle contain some 400-5000 glutamate 
molecules (Clements, 1996), which is a broad range. Second, the morphology of the 
synapse matters. Most of the glutamate transporters are located on astrocytes. If the 
transporters shall contribute to clear the glutamate, they must be located near the 
glutamate release sites. Because localization of astrocytes in relation to synapses varies 
between regions and different synapses, the role of glutamate transporters will also vary. 
Third, the number of glutamate transporters will be important. The high number of 
glutamate transporters are sufficiently high to clear the number of glutamate molecules 
released per vesicle. Since the glutamate transporters are slow (about 70 ms per cycle 
(Wadiche et al., 1995; Auger and Attwell, 2000), they compensate by their high number 
and high affinity that easily make them “buffer” the extracellular glutamate. GLT1 clears 
most of the glutamate with its high number and localization in astrocytic membranes 
close to synapses, GLAST and EAAC1 seem to play minor roles. It is likely that 
glutamate transporters serve at least dual functions both as a transporter of other 
substances than glutamate and as an ion-channel (Ryan et al., 2004; Veruki et al., 2006). 
Why there are five different glutamate transporters and several splice variants that are so 
differentially expressed and regulated is a question. 
 
The physiological roles of glutamate transporters 
It is obvious that glutamate transporters play a significant role in removing glutamate 
from the extracellular space. The abundance and importance of GLT1 is also evident 
from the phenotype of GLT1 deficient mice. In mice deficient in GLT1 glutamate levels 
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rise enough to cause epilepsy and cell death (Tanaka, 1997). Similarly, the GLAST 
knockout mouse show reduced motor coordination and have major changes in the retina 
(Watase et al., 1998), which is in agreement with the localization of GLAST. The 
EAAC1 knockout do not develop remarkable neurological symptoms, except for reduced 
spontaneous locomotor activity and dicarboxylic aminoaciduria (Peghini et al., 1997). 
EAAC1 also transports cysteine with an affinity 10–20-fold higher than that of GLAST 
or GLT-1 (Zerangue and Kavanaugh, 1996b). A recent study demonstrated age-
dependent neurodegeneration with decreased glutathione (GSH) content, increased 
oxidant levels and increased susceptibility to oxidative stress in EAAC1-deficient mice 
(Aoyama et al., 2006). These EAAC1-deficient mice also showed an age-dependent 
decrease in neuronal number in the substantia nigra (Aoyama et al., 2008a). GSH plays 
an important role in detoxifying reactive oxygen species (ROS) and thereby protecting 
cells from oxidative stress (for review see Dringen, 2000). GSH is a tripeptide composed 
by cysteine, glycine and glutamate where cysteine is the rate-limiting factor for GSH-
synthesis in neurons. In primary neuron culture, approximately 90% of total cysteine 
uptake is mediated by sodium-dependent systems, mainly excitatory amino acid 
transporters (EAATs) (Chen and Swanson, 2003; Himi et al., 2003).  
 
Glutamate transporters and disease 
Malfunction of glutamate uptake has been reported in many diseases, but it is not easy to 
differentiate between cause and effect of dysfunction of glutamate transporters (for 
review, see Danbolt, 2001;Beart and O'Shea, 2007).  The role of glutamate transporters in 
disease are often connected to glutamate as a neurotoxin. At high extracellular 
concentrations glutamate is toxic to the brain and can contribute to neuronal cell death 
(Choi, 1992). If the extracellular glutamate is increased more glutamate will bind to 
glutamate receptors. Binding to the ionotropic glutamate receptors will give more 
glutamate release and an influx of Na+ and Ca2+. The cells energy consumption will 
increase in order to pump these ions out again. In addition free radical production will 
increase (Bondy and Lee, 1993). This may in turn impair energy production and 
glutamate uptake, and maybe even reverse glutamate transporters causing further 
 19
glutamate release. An increase in extracellular glutamate concentration easily starts 
vicious circles. 
 In ischemia, hypoxia and hypoglycemia, ion gradients dissipate, glutamate 
transporters reverse and a massive efflux of glutamate and cell death is the result 
(Nicholls and Attwell, 1990; Rossi et al., 2000). In addition there is a vesicular release 
(Drejer et al., 1985) and release through swelling-activated anion channels (Kimelberg 
and Mongin, 1998). It is still debated from which compartments most of the glutamate 
leak during ischemia (Ottersen et al., 1996; Lipton, 1999). The most favored hypothesis 
is that the glutamate comes from neurons because most brain glutamate is stored there. 
Further, the glutamate uptake in glia cells are less sensitive to hypoxia than the neuronal 
uptake (Swanson et al., 1994). Quantitative immunocytochemistry studying the changes 
in glutamate concentrations following brain ischemia strongly suggest that the release of 
glutamate is by neurons (Ottersen et al., 1996), and by the dendro-somatic compartments.  
 ALS-amyotrophic lateral sclerosis is characterized by muscular weakness, 
atrophy and spacticity (Chancellor and Warlow, 1992). It is caused by death of motor 
neurons where exitotoxicity is one possible reason. A dramatic loss of GLT1 in ALS-
patients have been shown (Rothstein et al., 1995), but another paper has shown no change 
(Milton et al., 1997). Whether reduced GLT1-expression is a primary event leading to 
motor neuron death or if it is secondary to the neuron death is not clear. 
 Also in Alzheimer's disease there are several contradictory findings about reduced 
levels of GLT1 (Li et al., 1997) while another report found no correlation between 
reduced GLT1 levels and Alzheimer (Beckstrøm et al., 1999). It has been suggested that 
oxidation is a cause of disturbed GLT1 expression and that GLT1 splice variants occur in 
several neurological diseases like Alzheimer and ALS (Honig et al., 2000). 
 It has been observed elevated levels of glutamate in patients with various epilepsy 
(e.g. Janjua, 1992). And mice deficient of GLT1 develops spontaneous seizures (Tanaka, 
1997). In contrast to the mentioned neurological disorders it is questioned if it is too 
much glutamate transport in schizophrenia (for review, see: Carlsson et al., 1997). A 
glutamatergic hypofunction can be due to hyperactive glutamate transporters, defective 
receptors, lack of receptors, inadequate glutamate release or lack of glutamatergic nerve 
terminals. 
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AIMS 
The overall aim of this thesis has been to increase our insight into glutamatergic 
transmission and reuptake by providing quantitative data on the distribution and 
expression levels of the various glutamate transporter subtypes. The thesis has specially 
searched to give answer to these questions: 
-What is the functional significance of EAAC1?  
-Which transporter is responsible for the uptake of glutamate into nerve terminals?  
- How abundant are the various C-terminal variants of GLT1? 
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Methods 
I will here give an overview of the main methods I have used in this study focusing on 
principles without repeating all the details as they are described in the papers. 
 
Tissue preservation-fixation 
The purpose of fixation is to preserve the tissue components of interest after death and 
during the cutting and labeling procedures. It is important to realize the type of fixative 
and the type of fixation procedure have to be adapted to the purpose. The fixation should 
preserve the structures without impairing detection. Because fixation is usually only the 
beginning of a long process, and it is important to consider the entire procedure before 
fixing the tissue. 
 Fixatives: These are chemicals that chemically modify the tissue in such way that 
the desired preservation is obtained. The most common is formaldehyde which binds to 
and make covalent bonds between adjacent amino groups. Formaldehyde has a tendency 
to polymerize, and the polymer diffuses slower into the tissue. To get an efficient and 
quick fixation it is important to work with monomers. This is usually accomplished by 
depolymerizing paraformaldehyde to formaldehyde shortly before use. Glutaraldehyde 
works in the same way, but is a slightly larger molecule which diffuse slower, but being a 
di-aldehyde it forms cross-links more efficiently. This is an advantage with respect to 
immobilizing diffusible molecules and with respect to preservation of ultrastructure, but 
not when it comes to antigen accessibility. Note that fixation time, concentration and 
temperature are just as important parameters as the choice of chemical compounds. 
 Fixation procedure: Small tissue pieces can be efficiently fixed simply by 
immersing them in fixative. The best fixation of thicker tissue (like a whole brain) is 
obtained by a perfusion of the animal through the heart. The animal is given a lethal dose 
of pentobarbital, then a tubing with a needle is put into the left ventricle-aorta and the 
fixative delivered through the tubing by a peristaltic pump.  
 
Preparation of antibodies 
Antibodies are immunoglobulins, proteins which specifically recognize their antigens. 
They are composed of two heavy and two light chains and are Y-shaped, the two heavy 
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chains are connected together by disulfide-groups. Between the light and the heavy chain 
there is an antigen binding site. In research antibodies are used to identify and localize 
proteins. 
 
 
Antibodies have been made by immunizing animals with the antigen of interest. We have 
mostly used synthetic peptides corresponding to parts of the protein. The advantages with 
using short peptides are that we can avoid conserved parts and thereby avoid cross-
reaction with other proteins. Further we know exactly which part of the protein it reacts 
to and the antibody can so be used in functional studies of the transporter proteins. The 
disadvantage with antibodies against short peptides is that they may not recognize the 
native protein, only the peptide, and it can be difficult to choose the most antigenic parts 
of the protein. Special computer programs exist that can help us choose the most 
hydrophilic and assumed most antigenic parts of the protein. But the programs only give 
an indication.  
EAAC1 
GLT1 
Figure 4: Antigenicity plot of EAAC1 and GLT1. Hydrophilic parts are shown in blue and the 
predicted antigen parts in pink.  
  
It can be good to avoid transmembrane parts, as well as glycosylated and lipidated parts. 
Also cysteines should be avoided as they tend to make trouble during synthesis (Danbolt 
et al., 1998). But there are no absolute rules. From Figure 4 one can think that it should 
not be more difficult to produce antibodies to EAAC1 than to GLT1, but our experience 
and paper I shows that this is not the case.   
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The peptides must be coupled to a carrier as they are too small to be antigenic (molecules 
less than 1-5 kDa are normally not antigenic). We have used keyhole limpet hemocyanin 
(KLH), BSA or thyroglobulin as carrier proteins. The peptides are then coupled to the 
carrier by glutaraldehyde. Most often we have used rabbits for the production. They 
respond well and give 70-80 ml serum per month. The antibodies are affinity purified by 
immobilized peptide, the same as the animal was immunized with. If the antibody show 
unwanted reactivity, they should also be absorbed. Then the carrier-protein is coupled to 
agarose and aldehyde treated, and the sera is run slowly through this column.  
 
Immunohistochemistry  
Immunohistochemistry followed by microscopy is useful for studying a protein’s 
localization at regional, cellular and subcellular level. Multiple labeling can also be done 
with different fluorochromes in order to compare labeling of several proteins at the time 
and see whether they colocalize or not.  
Briefly, mice or rats are perfusion fixed, tissue taken out and cut on vibratome. The 
sections are blocked and incubated with primary antibody. The immunoreagents will 
diffuse into the section from the surface. The antigen-antibody complexes are visualized 
with biotinylated anti-rabbit IgG and streptavidin-biotinylated horseradish peroxidase 
complex followed by diaminobenzidine (DAB) for ordinary light microscopy or 
fluorescent dye for confocal microscopy.  
 
Pre-embedding peroxidase labeling: Pre-embedding means labeling of the tissue before it 
eventually is embedded and processed for electron microscopy. Pre-embedding 
peroxidase labeling transforms the substrate diaminobenzidine into a precipitate that will 
be restricted by the cell membranes. This precipitate is electron dense so that the sections 
can also be used for electron microscopy if wanted. This is a sensitive method and has the 
advantage that the sections can be viewed light microscopically first. Interesting parts of 
the section can be cut out and embedded in a plastic material (Durcupan®) for electron 
microscopy. The method is not quantitative as structures may be unlabelled either 
because they do not contain the antigen or because the antigen is not accessible. 
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Post-embedding immunogold: Post-embedding labeling means that labeling is done after 
embedding and cutting of the sections. The antibody-antigen complex is viewed with a 
secondary antibody coupled to a gold particle (the gold particle is electron dense) This 
method is quantitative and gives higher resolution as it can show in which parts of the 
membrane the protein is localized, but it is less sensitive than the pre-embedding 
labeling.  
 
 
Figure 5. Illustration of pre-embedding (left) and post-embedding (right) techniques. For pre-
embedding the reaction product is restricted by the cell membrane. For post-embedding the 
immunoreagents are not restricted by cell membranes. The length of the antigen-antibody 
complex is around 20 nm, so the gold particle can be on the outside of the structure although the 
antigen is on the inside (reproduced from Danbolt et al., 1998). 
 
Microscopy 
For ordinary light microscopy the resolution is limited by the wavelength of the light 
used. The resolution (d) is decided by the formula: d=(0.61x)/NA where  is the 
wavelength of the light and NA is the numerical aperture. Optimally the resolution can be 
0.2 m, but most often it is closer to 0.5 m. This means that the light microscope is 
excellent for getting an overview over which part of the section and which structures that 
are labeled, but the subcellular labeling needs higher resolution. For instance nerve 
terminals which are about 500 nm will appear as dots in this microscope. 
The electron microscope has high resolution and is extremely powerful for detecting the 
exact position of a protein at the ultrastructural level. Here the light is replaced by an 
electron beam, which has a wavelength of 0.005 nm. Since the resolution is proportional 
with  it gives a very high resolution, normally around 0.2 nm 
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For fluorescent microscopy the antigen-antibody complex is viewed with a fluorescent 
dye (or particle like e.g. quantum dot) with a certain excitation and emission spectrum. 
Since fluorescent dyes exist with different emission spectra it can be performed multiple 
labeling. For multiple labeling you have to ensure that the emission spectra do not 
overlap. This allows us to study colocalization of proteins. The immunofluorescence 
technique requires application of antibodies which must be carefully validated by 
appropriate control experiments.  
 
In a conventional (i.e., wide-field) microscope the entire specimen is evenly illuminated 
resulting excitation of the entire section thickness. Light originating from the parts of the 
section that are out of focus often causes a strong background. The background from 
unfocused parts can be avoided by using confocal microscopy. The confocal microscopy 
provides sharper images than the conventional microscope since it excludes light from 
outside the focal plane. Each image represents a thin cross-section of the specimen. It is 
also possible to obtain a three-dimensional reconstruction by sampling several images 
along the vertical axis of the specimen. The resolution of confocal microscopy is close to 
the theoretical limit (see above). 
 
Western blotting 
The purpose of blotting is to transfer the molecular species from the matrix of a gel 
(agarose or polyacrylamide) and to the surface of a membrane (nitrocellulose, PVDF, 
nylon or others) where they can be studied much more easily. In general proteins in a 
tissue homogenate are separated by molecular weight by SDS-PAGE (Laemmli, 1970). 
The proteins are subsequently transferred from a gel to a membrane The protein can then 
be immunolabeled with the desired antibody. Probed antigens can be visualized by a 
variety of secondary antibodies conjugated to e.g alkaline phosphatase or horseradish 
peroxidase. The immunocomplex can be detected by different methods like 
chemoluminecence, fluorescence or radioactivity. The method can be quantitative if 
specific controls or calibration systems are included. It is then important to work within 
the linearity of the signal. We used chemoluminecence which is a very sensitive method, 
the signal was captured by films or a CCD camera (a CCD camera converts optical 
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brightness into electrical amplitude using charge coupled device (CCD), the signals can 
be converted to digital values). Films are very sensitive, but the CCD camera can capture 
linear data over a broad range. The CCD camera gives digital recording and very short 
exposure times can be done. In such a way saturation during image acquisition can be 
avoided. It is very important to ensure precise loading of the gel and to repeat the 
experiments in triplicates. 
Immunoblotting with purified protein extended the linear range upwards, but reduced 
linearity at low protein amounts presumably due to non-specific loss of protein. In paper 
IV this loss was prevented by adding 1 g of total brain proteins from GLT1-deficient 
mice to all samples containing purified GLT1 protein (thus, the amount of purified 
proteins loaded was varied, but the amount of unrelated brain tissue proteins was kept 
constant). It is also important to save pictures from different exposure times in order to 
analyze the linearity of the exposure times. 
 
Immunoisolation of proteins 
Immunoisolation of proteins is purifying a protein by means of immobilized antibodies. 
The antibodies are first coupled to a solid phase material (like Protein-A-Sepharose Fast 
Flow, which is Protein A coupled to Sepharose beads). Protein A is the most known IgG 
binding protein. It is a Fc-receptor that means it can bind to the Fc part of the antibody, 
keeping the antigen binding site free to bind to the antigen. The antibody is then used to 
pull out the antigen from a tissue or cell extract. The antibody is covalently bound to the 
Protein-A-Sepharose by dimethyl suberimidate to ensure that the antibodies do not fall 
off in the last step when a low pH buffer is added. Brain tissue or transfected cells are 
homogenized in a suitable buffer. We have often used SDS as a detergent to be sure that 
the tissue is properly dissolved. After homogenization we have added Triton to make the 
solution antibody “friendly” before incubation with the immobilized antibodies. 
Immobilized antibodies were incubated with the extracts for 1–2 h before the proteins 
were eluted with a low pH-buffer  The eluted proteins are then neutralized. Protease 
inhibitors and a reducing agent to avoid oligomerization of the transporter proteins are 
added to the eluate. 
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Cell culturing and transfection of mammalian cells 
Cell culturing is a method where cells can be kept alive ex vivo. By keeping optimal 
conditions the cells can grow. By transfecting the cells with foreign DNA of a protein of 
interest, the cells can express the proteins we want. In paper IV we wanted to verify that 
the antibodies to the GLT1 subtypes also could distinguish between the individual splice 
variants on immunoblots (as brain tissue contains a mixture of them), HEK293T (human 
embryonic kidney cell cultures) cells were transiently transfected with cDNA encoding 
GLT1 variants, solubilized in SDS, subjected to SDSPAGE and immunoblotted with the 
antibodies. The HEK293T-cells did not have detectable endogenous expression of GLT1, 
neither non-transfected cells nor cells transfected with an open vector were 
immunopositive The GLT1 subtypes were immunoisolated with subtype specific 
antibodies from the transfected cells.  
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SYNOPSIS 
 
Summary 
Glutamate is the major excitatory neurotransmitter in the mammalian nervous system. It 
is inactivated by cellular uptake catalyzed by a family of glutamate transporter proteins 
(GLT1, GLAST, EAAC1, EAAT4 and EAAT5). The main aim of the present thesis was 
to determine the contributions of the individual glutamate transporter subtypes to the total 
glutamate uptake around hippocampal synapses focusing on the EAAC1 subtype and on 
the mysterious transporter responsible for nerve terminal uptake of glutamate. The first 
step on this endeavor was to make antibodies to EAAC1. As outlined in Paper I, it turned 
out to be more difficult to make good antibodies to EAAC1 than to the other glutamate 
transporters. Specificity testing using tissue from EAAC1 knockout mice as negative 
controls revealed highly specific interactions with unrelated proteins. Paper II 
summarizes of the lessons learnt about immunocytochemical specificity testing, and 
Paper III illustrates how the antigen pre-adsorption test can be misleading. After having 
overcome methodological problems, we were in position to address the original question. 
In Paper IV a new procedure for immunoisolation of EAAC1 was developed, and known 
amounts of pure EAAC1 protein was used as standard to quantify EAAC1 concentrations 
in brain tissue extracts. EAAC1 was found to be present at 13 g per gram hippocampal 
protein. This is 100 times less than GLT1 and argues against a significant contribution of 
EAAC1 to rapid transmitter activation. EAAC1is selectively expressed in neuronal 
somata and dendrites throughout the brain, and thereby in a total surface area similar to 
that of astrocytes. In Paper V we show that nerve terminal glutamate uptake fully 
depends on GLT1, and that about 10% of hippocampal GLT1 protein is expressed 
terminals. This also explains why high levels of GLT1 mRNA is present in CA3 
pyramidal cells. In Paper VI we describe antibodies to GLT1 splice variants and show 
that GLT1a represents about 90 % of total hippocampal GLT1, while GLT1b and GLT1c 
represented 6 and 1 %, respectively. We also provide the first data on the distribution of 
the GLT1b and show that this variant does not contribute to nerve terminal uptake. 
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Comments on original papers 
Comments on paper I:  Specificity of antibodies: Unexpected cross-reactivity of 
antibodies directed against the excitatory amino acid transporter 3 (EAAC1) 
glutamate transporter  
 
Background: We wanted to quantify and localize EAAC1 in order to gain insight into its 
physiological functions. Because we initially did not have access to EAAC1 knockout 
mice, we made several antibodies to different parts of the EAAC1 protein molecule in 
order to be as sure as possible about the specificity. Our group had already made 
antibodies the C-terminus (residues 491-523 and 510-523) before I got involved. These 
antibodies gave rise to weak labeling on Western blots, but remarkably strong labeling in 
tissue sections. This mismatch made us feel uneasy. Another factor that made us feel 
uneasy was that preferential labeling of cytoplasm. Further, there were some data in the 
literature based on antisense knockdown of transporters attributing about a third of the 
total glutamate uptake activity to EAAC1 (Rothstein et al., 1996). We then noted that 
other investigators (Kugler and Schmitt, 1999) had made antibodies to a peptide 
corresponding to residues 480-499. They got strong labeling and described colocalization 
of EAAC1 and tubulin. We wondered if Rothstein and co-workers (1996) could be right 
after all.  
 
Results: We made antibodies to a peptide similar to that of Kugler and Schmitt (1999), 
and like them, we also got antibodies that recognized a strong band.  The electrophorectic 
mobility, however, was slightly higher than that of the band recognized by the other 
antibodies. Nevertheless, we got excited because this could mean that we were about to 
discover a novel and much more abundant variant of EAAC1. To be sure that this protein 
indeed was EAAC1, it was decided to try to immunoisolate it to get a protein sequence. 
Then we discovered that the protein was sometimes in the water soluble fraction and 
sometimes in the membrane fraction. This did not make sense. Further, the antibodies 
labeled axons strongly. Using a robotic ELISA system, I screened the antibodies for 
reactivity towards a number of non-EAAC1 proteins, including actin and tubulin which 
 31
are abundant in axons. The antibodies reacted strongly with tubulin and did so with a 
remarkable specificity. This explained why the protein was sometimes in the water 
soluble fraction: it was there when the conditions favored depolymerization of tubulin! I 
then fractionated the antiserum and obtained one fraction that recognized both tubulin 
and EAAC1, and another fraction that appeared specific for EAAC1. The EAAC1-
specific fraction did not label axons. The labeling appeared restricted to the 
dendrosomatic compartment. There was no labeling of oligodendrocytes and no labeling 
of astroglia. 
       In parallel with this, we also made antibodies to a number of other EAAC1 peptides 
using different immunization protocols. 
 
Discussion:  This paper offers an explanation to why Kugler and coworkers observed a 
colocalization between EAAC1 and tubulin anf thereby concluded that EAAC1 is also in 
oligodendrocytes: their antibody probably also cross-reacted with tubulin. Unfortunately, 
their antibody was not available when we asked them for a sample so this hypothesis 
could not be tested directly. It is important to add that Kugler and co-workers only had 
one antibody and they did not have access to the EAAC1-knockout. This means that they 
did not have the means to uncover the reactivity with tubulin. Further, I had a robot to do 
the ELISA assays for me. During this work it became clear to us that the majority of 
antibodies against synthetic peptides do not recognize the native protein, and that cross-
reaction with unrelated proteins is very common. Importantly, it also suggests that the 
pre-adsorption test has little value when testing affinity purified antibodies.  
 
 
Comments on paper II: Specificity controls for immunocytochemistry 
 
Background: Still the goal was to quantify and localize EAAC1. To be sure about the 
specificity of our antibodies when used to label tissue sections we got hold of fixed brains 
from EAAC1 knockout mouse previously described (Peghini et al., 1997).  
 
 32
Result: This final test of the antibodies against EAAC1gave a surprising result: despite 
the testing described in Paper I and despite being specific on immunoblotting, the 
antibodies did label something in the EAAC1 knockout. So instead of getting the data I 
wanted, I ended up knocking out my own paper. In stead, we summed up all the lessons 
learnt in this paper. 
 
Discussion: This paper is intended as a guide for immunocytochemistry. Too many 
papers are published without proper controls, and it is frustrating to see this. Everybody 
should test their antibodies carefully before they go ahead using them. It is bad to have 
spent a lot of time on antibodies that are not specific. It is also bad for others that wrong 
results are published, and it is costly to correct erroneous data published by others. The 
latter point is illustrated in Paper V.  
 
 
Comments on paper III: Specificity controls for immunocytochemistry: the antigen 
pre-adsorption test can lead to inaccurate assessment of antibody specificity 
 
Background: A widely used test for verification of antibody specificity is the pre-
adsorption test, in which the antibody is mixed with the antigen used to generate the 
antibody. If addition of the antigen to the antibody prior to incubation with the sample 
(tissue sections or Western blots) removes the ability of the antibody to label, then this is 
taken as proof of specificity. It is, or rather, it should be well known that this test has 
major limitations as pointed out before (e.g. Pool and Buijs, 1988; Swaab et al., 1977; 
Burry, 2000; Holmseth et al., 2005; Holmseth et al., 2006). Nevertheless, this test 
continues to be used, sometimes as the only specificity test. We decided to look a bit 
more into this and to illustrate the point. 
 
Results: We tested the specificity of several antibodies by using different tests; by 
performing the antigen pre-adsorption test, by immunoblotting, by using several 
antibodies to the same antigen, and by using tissue from knockout mice as negative 
controls. We show that antigen pre-adsorption blocks all binding of the affinity purified 
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antibodies for the selected antibodies shown here (antibodies to GLT1, EAAC1 and 
BGT1), regardless of whether this binding is to the transporters under study or to cross-
reacting epitopes. Further, we demonstrate that there is no perfect correlation between 
specificity of labeling seen on immunoblots and labeling seen in sections. This goes both 
ways. Labeling in sections may be due to cross-reactivity even if the blots look perfect, 
and labeling in sections may be specific even if the blots are dirty. Extra bands on a blot 
represent a warning, but are in themselves not an absolute indicator and thereby not a 
sufficient argument for rejecting a study if there are other reasons to believe that the 
labeling is specific (e.g. no labeling in sections from a knockout mouse).  
 
Discussion: This shows that the pre-adsorption test does not confirm the identity of the 
antigens being labeled. Pre-absorbing the antibodies is an alternative to affinity 
purification in the sense that it shows if the labeling is due to the right antibodies, but this 
does not tell what the same antibodies bind to in the samples. It can be used as a test 
when unpurified serum is used because serum contains several antibodies. This test is so 
widely used that it is important to make people aware of its limitations. 
 
 
Comments on paper IV: Low density of EAAC1 (EAAT3; slc1a1) glutamate 
transporters suggests involvement in neuronal metabolism rather than in rapid 
control of synaptically released glutamate 
 
Background: In papers I-III we have described the difficulties we had with obtaining 
specific antibodies to EAAC1. The antibodies we had were specific on immunoblots, but 
when they were tested on tissue sections, they all gave labeling in the knockout. We had 
no antibody that was suitable for immunocytochemistry. Finally we managed to purify 
one antibody that was monospecific to EAAC1. This antibody was used to study 
EAAC1’s localization, now with the EAAC1 knockout as control. 
 
Results: This paper consists of four main elements. The first element is the purification 
of EAAC1. We first tried to purify EAAC1 from brain, but found out that it was easier to 
 34
do this from kidney. After having developed a new purification protocol by modifying 
the procedures used with success for GLAST and GLT1, pure EAAC1 protein was 
eventually obtained, although in small amounts. The second main element is the 
determination of EAAC1 concentrations in brain tissue by immunoblotting using known 
amounts of pure EAAC1 protein as standards. The EAAC1 concentration in the young 
adult hippocampus was found to be about 100 times lower than that of GLT1. The third 
element was the generation of a specific EAAC1 antibody to allow localization. The 
strategy that finally gave rise to good  antibodies was somewhat unusual: to grow 
anaerobic bacteria from rabbits and use extracts from these to absorb and remove 
unwanted antibodies from antisera prior to affinity isolation on columns with 
immobilized peptide. EAAC1 was found to be restricted to neuronal cell bodies and 
dendrites. EAAC1 was not detected in axon-terminals. Most EAAC1 is intracellular. The 
fourth main element is the determination of the surface area of dendrites and spines, and 
then to calculate the number of EAAC1 molecules using molecular mass, concentration 
(gm/liter) and membrane surface area. 
 
Discussion: This paper corrects the literature in several ways. Firstly, we bring to rest the 
question of whether EAAC1 is expressed in glia or in terminals. Secondly, we address the 
question of the concentrations and show that there are not enough EAAC1 molecules to 
capture any significant proportion of released glutamate molecules before they can 
escape from the synaptic cleft even if the highest EAAC1 concentration should be, as 
claimed (Conti et al., 1998), in the spine membrane around the postsynaptic density. With 
a mean maximum density (assuming all EAAC1 is inserted in the membrane) of 90 
EAAC1-molecules per m2 , and a perisynaptic zone of about  0.2 m2  it follows that 
there may be around 20 EAAC1 molecules per synapse (or six trimers). The number of 
glutamate molecules released from a synaptic vesicle is believed to be in the range 500-
5000. Even if we assume that all of the monomers can bind glutamate, it follows that 
EAAC1 is able to catch only about 4 % of the glutamate molecules if 500 are released 
and 0.4 % if 5000 are released. This makes it clear that EAAC1 is expressed at too low 
levels to make a significant contribution. Further, EAAC1’s ultrastructrural localization is 
uncertain because the post-embedding technique is not sensitive enough. It is also clear 
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that it is GLT1 that removes most of the synaptic glutamate. The low density of EAAC1 
and that it is localized outside the synapses suggest that EAAC1 is not important for 
removal of extracellular glutamate, but that it may be important for neuronal metabolism 
because it is the only glutamate transporter expressed in the somato-dendritic 
compartment of most neurons. This agrees with the claim that EAAC1 is involved in 
neuronal glutathione synthesis (Aoyama et al., 2008b) as EAAC1 is the primary route for 
cysteine uptake.  
 The one uncertainty with this work is whether there are splice variants of EAAC1. 
We only have antibodies against the C-terminal available. So the immunoprecipitations 
and the following immunoblotting are both done with a C-terminal antibody. It is then 
possible that only a fraction of the EAAC1 protein is detected. On the other hand nobody 
has reported splice variants of EAAC1. 
 
Comments on paper V: A quantitative assessment of glutamate uptake into 
hippocampal synaptic terminals and astrocytes: New insights into a neuronal role 
for excitatory amino acid transporter 2 (GLT1) 
 
Background: It was concluded several decades ago that nerve terminals can take up 
glutamate (for review, see Fonnum, 1984; Ottersen and Storm-Mathisen, 1984; Danbolt, 
2001). In fact, many believed that terminals had more uptake activity than glia. This 
conclusion, however, was weakened by the combination of the findings that GLT1 is 
present in astrocytes and accounts for 95 % of the total reconstitutable uptake activity 
(Danbolt et al., 1992), and that glial expression of GLT1 depends on intact nerve 
terminals (Levy et al., 1995). The presence of GLT1 in terminals was then investigated 
electron microscopically using antibodies to glutaraldehyde fixed D-aspartate. It was then 
shown that terminals do have glutamate uptake activity and that this is sodium dependent 
and is able to concentrate (Gundersen et al., 1993). At this time it was not known that the 
GLT1 can be selectively inhibited by dihydrokainate and this drug was therefore not 
tested. However, synaptosome preparations are inhibited by dihydrokainate (Johnston et 
al., 1979; Robinson et al., 1993), but it could be argued that such preparations are 
contaminated with glia containing GLT1. And all antibodies that had been made against 
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GLT1, by several different groups, labeled only glial cells in tissue sections. Another 
puzzling observation was the high levels of GLT mRNA in some neurons ((Torp et al., 
1994; Schmitt et al., 1996; Torp et al., 1997); Berger and Hediger, 1998). Further, the 
GLT1 knockout mice had virtually no uptake activity (Tanaka et al., 1997). Taken 
together, this did not add up.  
 
Results: We repeated the electron microscopy experiments by Gundersen and co-workers 
(1993) and show that the uptake into terminals is sensitive to dihydrokainate like the 
uptake into astrocytes. Further, we show that nerve terminals in tissue from the GLT1 
knockout mice do not have the ability to accumulate D-aspartate. The uptake activity of 
terminals represents about half of the uptake activity in slices, and about three quarters of 
that in synaptosome preparations. We did not find any uptake of D-aspartate into spines, 
the structures that express EAAC1, that is another indication for that EAAC1 does not 
contribute much to removal of extracellular glutamate. We then noticed that the 
hippocampal slices have much larger extracellular spaces after in vitro incubation than 
normal perfusion fixed tissue. This meant that the various tissue components are better 
separated. We made use of this and did post-embedding immunogold for GLT1. Then we 
managed to show that terminals do express GLT1 protein. Most of the immunoreactivity 
is found in glial structures (about 80%), but some 5-10% is present in terminals. Some of 
the immunoreactivity (8%) was found in axons where it was distributed in a plasma 
membrane surface area several times larger than that of astroglia. This explains why CA3 
pyramidal cell bodies have high levels of GLT1 mRNA. 
 In the mean time others (Chen et al., 2002) claimed that terminals express the b-
variant of GLT1. We then showed that the a-variant is the predominant isoform in the 
terminals, but before we managed to publish the proof, they corrected themselves (Chen 
et al., 2004) explaining that their antibodies were not specific and that terminals express 
the a-variant.  
 
Discussion: This work resolves the question of whether the glutamate uptake into nerve 
terminals is mediated by GLT1 and why CA3 pyramidal cells have GLT1 mRNA. It also 
support the notion that synaptosome preparations preferentially measure uptake into 
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terminals. However, the study left us with another question: how can 5-10 % of GLT1 
molecules account for half of the uptake activity? This mismatch could be explained by 
damaged glial cells. Glial cells have a lot of processes and probably many of them will be 
cut off during the slice-preparation. This explains why the glial cells look collapsed in the 
slices. The nerve terminals seem to manage the slice-preparation better. They are small, 
round structures which seem to be well preserved during a slice-experiment. It needs to 
be done more studies on how the glial cells manage during these slice experiments. It is 
also a question whether glutamate uptake mediated by GLT1 is differentially regulated in 
nerve terminals versus glial cells (Xu et al., 2003; Furness et al., 2008). The capacity of 
the nerve terminal uptake in relation to glial uptake is not known, and we do not know 
how this uptake is in intact brain. To follow up glial versus nerve terminal glutamate 
uptake we have floxed the GLT1 gene by adding LoxP-sites to it. In combination with 
expression of Cre-recombinase this will delete GLT1 in the mouse. The construct works 
because crossing these animals with Nestin-Cre abolished GLT1 expression in the 
nervous system.  
 
Comments on paper VI: The concentrations and distributions of three C-terminal 
variants of the GLT1 (GLT1; slc1a2) glutamate transporter protein in rat brain 
tissue suggests differential regulation 
 
Background: In paper IV it was confirmed that GLT1a is expressed in nerve terminals, 
although at low levels. But this paper did not address the question whether other variants 
could be present in terminals. Quantitative data on protein levels were missing  
 
Results: In this paper we make antibodies to three C-terminal variants of GLT1, and use 
these antibodies to quantify and localize the variants. To be able to obtain pure variant 
proteins, cells were transfected with the cDNA of the different proteins. The pure 
proteins were used as standards for the relative quantifications. Concentrations of total 
GLT1 protein were normalized using a pan-GLT1 antibody. We find that GLT1a 
represents about 90 % of total hippocampal GLT1, while GLT1b and GLT1c represented 
6 and 1 %, respectively. We also provide the first data on the distribution of the GLT1b 
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on the subcellular level. The antibodies to GLT1c did give some labeling in tissue 
sections, but we were unable to detect differences between wild-type and knockout mice. 
To document the GLT1 distributions in more detail, we also made a web-atlas for GLT1a 
and –b in collaboration with another group at the Centre for  Molecular Biology and 
Neuroscience. Series throughout a whole rat and mouse brain were cut and labeled with 
the antibodies. The section were scanned and can be viewed as high-resolution 
microscopic images showing GLT1 distributions. This is a virtual microscope in a data-
repository for online inspection and re-use (http://www.rbwb.org; choose “Atlas of 
Neurotransporter Distributions”).  
 
Discussion:  
Here, we addressed the question of whether other GLT1 variants also are expressed in 
nerve terminals indirectly by comparing the amounts relative to each other. We were not 
able to detect GLT1b in nerve terminals. Because GLT1b is expressed at levels around 15 
times lower than GLT1a, it follows that if GLT1b is in nerve terminals it must be at a 
level even lower than the GLT1a in terminals. It is valuable to know that the amount of 
the GLT1b and GLT1c is low in control tissue since it is speculated in that these variants 
are up-regulated in different neurological diseases. Having splice variants give 
possibilities for differential regulation and targeting for the different splice variants. We 
here show that GLT1 splice variants seem to be differentially regulated both during 
development and in regional expression. The same study should also be repeated on 
retina since these variants are expressed there. 
 
 
CONCLUSIONS 
The present work demonstrates the importance of proper antibody testing before use 
(Paper I), and that genetically modified animals is the best negative control for 
immunocytochemistry (Paper II). The pre-adsorption test is not a proper specificity test 
as pre-adsorption with the antigen also removes eventually unspecific labeling (Paper 
III). We show that it is important to determine the quantities of the glutamate transporters 
to answer whether it is enough of the protein for its proposed functional role. The level of 
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EAAC1 is about 1% of the GLT1 level. This together with EAAC1’s localization outside 
synapses mean that EAAC1 is unlikely contribute much to synaptic clearance of 
glutamate and probably plays  metabolic roles (Paper IV). GLT1 is the quantitatively 
dominating glutamate transporter. Although this transporter is predominantly in 
astrocytes, it is also the transporter responsible for the uptake of glutamate into nerve 
terminals (Paper V). Nerve terminals express GLT1a. GLT1b is only found in astrocytes. 
GLT1a represents about 90 % of total hippocampal GLT1, while GLT1b and GLT1c 
represented 6 and 1 %, respectively (Paper VI). 
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ABSTRACT 
Most of the high resolution data on the 
distribution of proteins in tissues have been 
obtained by means of immunocytochemistry, and 
the biomedical research community relies 
directly or indirectly on these data. For instance, 
interpretation of electrophysiological and 
pharmacological observations depends on 
information on where ion channels, receptors, 
enzymes  or transporters are located. 
Consequently, issues related to 
immunocytochemical quality control are 
important. Unfortunately, no single test has 
sufficient power to unequivocally validate 
labeling specificity. Several tests have therefore 
to be used in combination. One test is the "pre-
adsorption test". This test was intended for 
testing crude antisera, but is now frequently used 
to validate monoclonal and affinity purified 
polyclonal antibodies. Here we compare the 
power of this test with that of tests based on 
tissues from genetically modified animals, 
multiple antibodies to the same protein, and 
immunoblots (with or without fixation). We show 
data from nine different affinity purified 
antibodies to three proteins (slc1a1, slc1a2, and 
slc6a12) in combination with genetically modified 
mice deficient in these proteins. We demonstrate 
that the pre-adsorption test can be misleading. 
Further, we show that immunoblotting is more 
informative, but we also show examples where 
labeling of immunoblots does not match that seen 
in sections.  
 
 
 
 
 
 
 
 
Keywords: Antibody dilution, Glutamate 
transporter, GABA transporter, Knockout mice, Blot 
fixation test, Blocking peptide, Neoantigens  
 
 
INTRODUCTION 
Immunochemical techniques have been in 
widespread use for several decades for identifying 
individual proteins in complex biological samples 
(e.g. tissue extracts and sections), and the principles 
of immunocytochemistry are well established (e.g. 
Pool and Buijs, 1988). Nevertheless, the field of 
immunocytochemistry is still troubled by spurious 
results due to insufficient controls of antibody 
specificity. Inaccurate immunocytochemical data are 
a major concern, considering the widespread use of 
this method and the considerable effort required to 
correct inaccurate results. Several recent 
publications have addressed these issues and have 
proposed guidelines for inclusion of 
immunocytochemical data (e.g. Saper and 
Sawchenko, 2003; Saper, 2005; Holmseth et al., 
2006; Rhodes and Trimmer, 2006; Lorincz and 
Nusser, 2008; Fritschy, 2008; Burry, 2011). The 
arguments for improvements in quality control are 
strong, but it is hard to define the exact tests that 
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should be performed. One important step in this 
direction is to demand detailed descriptions of 
antibodies (e.g. Saper and Sawchenko, 2003; Saper, 
2005; Holmseth et al., 2006; Rhodes and Trimmer, 
2006; Fritschy, 2008). Another would be to motivate 
commercial antibody producers to test their 
antibodies more rigorously before selling them to 
scientists who often lack the resources or expertise 
to evaluate acquired antibodies (Pradidarcheep et al., 
2008; Couchman, 2009; Boenisch, 2006; 
Kalyuzhny, 2009). However, not all testing can be 
done in advance, because the overall labeling 
specificity is affected by so many parameters that 
antibodies have to be tested for each application 
(e.g: Ottersen, 1987; Holmseth et al., 2006; Lorincz 
and Nusser, 2008; Rhodes and Trimmer, 2006). 
Virtually all assay conditions can affect antibody 
binding, including protein conformation and 
hydrophobic interactions (e.g. pH, buffer 
composition and ionic strength), tissue handling 
steps (e.g. time to fixation, type of fixation, fixative 
composition, fixation time, storage after fixation) 
and antigen retrieval techniques (e.g. Josephsen et 
al., 1999; Willingham, 1999; Burry, 2000; Holmseth 
et al., 2006; Webster et al., 2009; Boenisch, 2006; 
Lorincz and Nusser, 2008; Saper, 2009; Hoffman et 
al., 2010; Paavilainen et al., 2010; Xie et al., 2011).  
 The scope of the present report is not to 
provide a comprehensive overview of all aspects of 
immunocytochemical specificity testing, but to 
compare the power of the antigen pre-adsorption test 
with other tests. Antigen pre-adsorption was 
originally introduced to validate antisera (e.g. Pool 
and Buijs, 1988; Swaab et al., 1977; Burry, 2000; 
Burry, 2011), but it is still considered mandatory by 
many investigators although it is now commonly 
used to validate labeling obtained with monoclonal 
or affinity purified antibodies. Here, we tested the 
specificity of several antibodies (a) by performing 
the antigen pre-adsorption test, (b) by 
immunoblotting, (c) by using several antibodies to 
the same antigen, and (d) by using tissue from 
knockout mice as negative controls. We show that 
antigen pre-adsorption blocks all binding of the 
affinity purified antibodies, regardless of whether 
this binding is to the proteins under study or to 
cross-reacting epitopes.  
 
MATERIALS & METHODS 
Animals, immunizations and collection of tissue 
All animal experimentation was carried out in 
accordance with the National Institute of Health 
Guide for the Care and Use of Laboratory Animals 
(NIH Publications No. 80-23) revised 1996 and the 
European Communities Council Directive of 24 
November 1986 (86/609/EEC). Formal approval to 
conduct the experiments described was obtained 
from the animal subjects review board of our 
institutions. Adult male Wistar rats (10-12 weeks 
old) were obtained from B&K Universal 
(Sollentuna, Sweden) and were kept at the animal 
facility of the Institute of Basic Medical Sciences at 
the University of Oslo (Oslo, Norway). The 
C57Black/6 mice (4 weeks old) lacking EAAT3 
(Peghini et al., 1997) were raised at the animal 
facility at the John Hopkins University (Baltimore, 
USA). The BGT1-fKO mice lacking the BGT1 
(slc6a12) gene were in a mixed [C57Blacl/6 x 129] 
background as described (Lehre et al., 2011), while 
the EAAT2-KO mice (Tanaka et al., 1997) lacking 
the EAAT2 gene (GLT1, slc1a2) were in a pure 
C57Bl/6 background. The mice were kept in the 
animal facility at the Governmental Institute of 
Publish Health (Oslo, Norway). The animals (both 
rats and mice) were killed by lethal injection of 
pentobarbital and fixed by cardiac perfusion as 
described previously (Danbolt et al., 1998). New 
Zealand White rabbits obtained from B&K 
Universal (Sollentuna, Sweden) were kept in the 
animal facility at the Institute of Basic Medical 
Sciences. Rabbits were immunized and bled as 
described (Danbolt et al., 1998), but using 
subcutaneous rather than intracutaneous injections.  
 The three genetically modified mouse lines 
were maintained by crossing heterozygote mice with 
each other. This was done to obtain pairs wild-type 
and knockout mice from the same litters. Thus, 
potential differences rearing conditions, genetic 
background and age were thereby minimized.  
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Table 1: Antibodies to transporter proteins were made by immunizing animals with synthetic peptides coupled to carrier proteins 
(keyhole limpet hemocyanin) with glutaraldehyde and then isolating the anti-peptide antibodies by affinity chromatography using 
columns with immobilized peptide (coupled to N-hydroxysuccinimide activated agarose) as described previously (Danbolt et al., 
1998). The antigenic sequences correspond to rat glutamate transporter 2 (EAAT2; NP_058911.2), rat glutamate transporter 3 
(EAAT3; NP_037164.3) and mouse betaine-GABA transporter (BGT1; P31651.1). The numbers in the peptide names and in the 
ligand names correspond to residue numbers in the sequences. The peptides were synthesized as C-terminal amides or free acids 
as indicated. A cysteine (C) residue was added to the N-terminal of the C491-523 peptide to facilitate directional coupling, but the 
successful immunizations resulted from coupling by adding glutaraldehyde to a mixture of peptide and carrier protein. Antibody 
#547 was raised against the C491-523 peptide and then affinity purified using immobilized tubulin. 
 
Antibodies to Excitatory Amino Acid 
Transporters (EAATs) 
The primary antibodies used in the present study are 
summarized in Table 1. The rabbit antibodies to 
different parts of rat EAAT2 (Pines et al., 1992) 
were from the same purified batches as described 
previously (Furness et al., 2008; Holmseth et al., 
2009). The batches of sheep anti-C510 (Ab#565), 
rabbit anti-C480-Tub (Ab#547) and rabbit anti-
C491 (Ab#371) antibodies to rat EAAT3 have also 
been described (Holmseth et al., 2005). They were 
made immunizing animals with peptides (Table 1) 
corresponding to residues 480-499 or 491-523 of rat 
EAAT3 (NP_037164.3). The antibodies are named 
after the peptide immobilized on the affinity 
columns. Thus, the anti-C480 and the anti-C491 
antibodies were affinity purified using the same 
peptide as the animals were immunized with, while 
the anti-C510 antibodies were collected on a column 
with a shorter peptide (corresponding to residues 
509-523).  
 When immunizing rabbits with the C480-
499 peptide, it was noted (Holmseth et al., 2005) 
that the ensuing antibodies cross-reacted with 
tubulin despite absence of primary sequence 
similarly with EAAT3. The antiserum was passed 
through a column with glutaraldehyde treated  
 
proteins (bovine serum albumin and keyhole limpet 
hemocyanin) to remove polyreactive antibodies, 
then through a column containing immobilized 
tubulin (to remove tubulin-binding antibodies), and 
finally through a column with immobilized EAAT3 
peptide. Antibodies detached from the latter column 
were devoid of tubulin reactivity (Ab#359, not 
shown here). The surprise was that the antibodies 
captured on the column with immobilized tubulin 
(anti-C480-tub; Ab#547) were able to recognize 
both the EAAT3 peptide and tubulin (Holmseth et 
al., 2005). 
 The rabbit anti-BGT599 (Ab#323) 
antibodies to BGT1 have not previously been 
published. They were made in the same way 
(Danbolt et al., 1998) as the other antibodies, but by 
immunizing a New Zealand White rabbit (number 
8D0156) with a peptide corresponding to residues 
599-614 (Table 1) of mouse BGT1 (slc6a12; 
accession number P31651; Liu et al., 1993) coupled 
to keyhole limpet hemocyanin with glutaraldehyde. 
The ensuing antiserum was affinity purified on a 
column with immobilized BGT599-614 peptide 
using our standard procedure (Danbolt et al., 1998). 
 
Electrophoresis and immunoblotting 
This was done as described (Lehre et al., 1995). 
Ab#
id 
Purification 
date 
Host 
species 
Antibody 
name 
Animal 
number 
Protein Antigen 
peptide 
name 
Antigen sequence Ligand on 
affinity column 
Specificity 
48 1993-06-19 Rb Anti-B2 81024 EAAT2 B2-11 ASTEGANNMP-(amide) 2-11 EAAT2 
360 2002-07-10 Rb Anti-B12 26970 EAAT2 B12-26 KQVEVRMHDSHLSSE-(amide) 12-26 EAAT2 
63 1994-06-05 Rb Anti-B372 82898 EAAT2 B372-382 RCLEDNLGIDK-(amide) 372-382 EAAT2 
95 1994-05-29 Rb Anti-B493 84946 EAAT2 B493-508 YHLSKSELDTIDSQHR-(amide) 493-508 EAAT2 
355 2002-09-05 Rb Anti-B563 1B0707 EAAT2 B563-573 SVEEEPWKREK-(free acid) 563-573 EAAT2 
359 2002-09-19 Rb Anti-C480 0B0721 EAAT3 C480-499 IVNPFALEPTILDNEDSDTK-
(amide) 
480-499 EAAT3 
371 2003-01-03 Rb Anti-C491 1B0683 EAAT3 C491-523 CLDNEDSDTKKSYVNGGFSVD
KSDTISFTQTSQF-(free acid) 
491-523 EAAT3 
547 2002-09-19 Rb Anti-C480-
tub 
0B0721 EAAT3 C480-499 IVNPFALEPTILDNEDSDTK-
(amide) 
Tubulin EAAT3 & 
Tubulin 
565 2005-10-31 Sh Anti-C510 4131 EAAT3 C491-523 CLDNEDSDTKKSYVNGGFSVD
KSDTISFTQTSQF-(free acid) 
509-523 EAAT3 
323 1999-04-28 Rb Anti-
BGT1(599) 
8D0156 BGT1 BGT1(599-
614) 
SPAKQELIAWEKETHL-(free 
acid) 
599-614 BGT1 
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Proteins were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
and electroblotted onto nitrocellulose membranes. 
Then blots were immunolabeled. Briefly, the blots 
were washed in phosphate buffered saline, incubated 
in blocking solution (blocking agent in tris buffered 
saline) followed by primary antibodies and alkaline 
phosphatase conjugated secondary antibodies. When 
not stated otherwise, the blocking agent was 1 % 
(w/v) bovine serum albumin and 0.05 % (v/v) 
Tween 20. 
 When stated, the tissue was homogenized in 
water and subjected to high speed centrifugation 
(18000 rpm, 39000 xg, 20 min, 4°C) to separate the 
water soluble components ("supernatant") from 
water insoluble ones ("pellet"). The pellets were 
solubilized in sodium dodecyl sulfate. Brain tissue 
contains about 100 mg protein per gram wet weight 
(Lowry et al., 1954). When homogenizing brain 
tissue in water (S. Holmseth and N.C. Danbolt, 
unpublished) about half of the proteins will remain 
in the supernatant which is virtually devoid of 
integral membrane proteins. Thus, this method is an 
easy way to increase sensitivity by a factor of about 
two for detection of transporter proteins. 
 
The blot fixation test 
After SDS-PAGE and electroblotting had been done 
as described above, but before the start of 
immunolabeling, the blots were washed (1 x 5 min) 
in 0.1 M sodium phosphate buffer, and then 
incubated with fixatives of the same composition as 
used to fix tissue for immunocytochemistry. After 
fixation, the blots were rinsed (1 x 1 min) in 0.1 M 
sodium phosphate buffer, incubated (30 min) with 1 
M ethanolamine or 2 M Tris-HCl buffer (pH 7.4) to 
quench aldehyde groups and then immunolabeled as 
described above. 
 
Light microscopic immunocytochemistry 
This was performed exactly as described previously 
(Holmseth et al., 2009). Briefly, free floating 
vibratome sections (40 m thick) were treated with 
1 M ethanolamine-HCl (pH 7.4) in sodium 
phosphate buffer, blocked with 10 % newborn calf 
serum (NCS) in TBST (300 mM NaCl, 0.5 % Triton 
X-100 and 100 mM Tris-HCl pH 7.4), and incubated 
overnight with primary antibodies diluted in 
blocking solution, followed by secondary 
antibodies. The alkaline phosphatase procedure used 
here was chosen because it has relatively low 
contrast and therefore reveals cross-reactivity better 
than enhanced chemoluminescence based 
procedures. The latter procedures typically have 
higher contrast and therefore give "cleaner" pictures. 
Omission of the primary antibody led to a virtually 
complete loss of labeling. This implied both that the 
secondary antibody did not cross-react with tissue 
components to any significant degree (Secondary 
antibody control) and that the tissue or immunoblots 
did not contain any functional enzymes able to 
convert the substrates (Label control).  
 
RESULTS 
Labeling of tissue sections: the pre-adsorption 
test versus gene deletion and multiple antibodies 
Antibodies to glutamate transporter 2 (EAAT2, 
slc1a2): Our laboratory has over the years produced 
239 different batches of antibodies to EAAT2 using 
51 different animals and 46 different synthetic 
peptides as well as purified EAAT2 protein. For the 
present study we selected five affinity purified 
antibodies (see Table 1) already known to recognize 
the native EAAT2 protein both before and after 
aldehyde fixation. Here we first tested the selected 
antibodies on sections from the EAAT2-knockout 
line (Fig. 1). The assay conditions were deliberately 
chosen to reveal cross-reactivity (high antibody 
concentrations and inclusion of Triton X-100 to 
enhance antibody penetration). As shown (Fig. 1) 
sections from wild-type mice were strongly labeled. 
The strong labeling was due to the combination of 
the labeling conditions, the properties of the 
antibodies and the fact that EAAT2 is very abundant 
in the brain representing about 1 % of total brain 
protein (Lehre and Danbolt, 1998). Under these 
conditions, only the anti-B372 antibodies produced 
strong labeling of forebrain sections from the 
knockout mice. In contrast, the anti-B2 or anti-B12 
to the N-terminal part of EAAT2 or anti-B563 to the 
C-terminus hardly produced any labeling at all in the 
EAAT2-deficient sections with the exception of the  
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Figure 1: Antibodies (Table 1) to five different 
EAAT2 epitopes were tested in brain and heart 
sections from wild-type and EAAT2 knockout 
mice. Some of the antibodies were pre-adsorbed 
overnight with 30 μg/ml of their respective 
peptide antigens (Ag), as indicated, before 
incubation with the tissue sections. Fixative: the 
mice were perfusion fixed with 4 % 
formaldehyde and 0.1 % glutaraldehyde in 0.1 
M sodium phosphate buffer (pH 7.4). Antibody 
concentrations: anti-B2 (Ab#48) 0.5 μg/ml; 
anti-B12 (Ab#360) 0.3 μg/ml; anti-B372 
(Ab#63) 0.5 μg/ml; anti-B493 (Ab#95) 0.2 
μg/ml; anti-B563 (Ab#355) 0.3 μg/ml. Some 
sections ("None") were developed without 
primary antibodies to control for the secondary 
antibodies and the label. Scale bar; 2 mm. 
 
cerebellar molecular layer. This layer was labeled in 
the sections from the knockout mice with all of the  
five antibodies, albeit very weakly with anti-B2 and 
anti-B563. At higher resolution (not shown) it could  
 
 
be seen that there were differences 
between the antibodies with respect to 
how they labeled the molecular layer, 
but all of them labeled Purkinje cells to 
some degree. The labeling observed in 
the molecular layer could not be due to 
EAAT2 because this is a conventional 
knockout and EAAT2 was completely 
knocked out in the rest of the brain. Pre-
incubation of the antibodies with 
peptide antigen prior to incubation with 
the sections eliminated all  
labeling, whether being specific for 
GLT1 or representing cross-reactivity.  
 It should also be pointed out that 
labeled Purkinje cells are not seen in 
sections from wild-type animals labeled 
with anti-B12 (not shown). This is not 
only because we would normally chose 
assay conditions that give less strong 
labeling, but also because of the huge amounts of 
EAAT2 in glial cells (Lehre and Danbolt, 1998). 
Thus, the anti-B12 antibodies are sufficiently 
specific in the adult cerebellum because of the low 
sensitivity needed to detect EAAT2.  
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Figure 2: Antigen pre-adsorption blocks all labeling including labeling of cross-reacting epitopes. The same two EAAT3 
antibodies as in figure 6, namely anti-C480-tub (Ab#547) and anti-C491 (Ab#371), were pre-absorbed overnight with 0, 60 or 
600 μg/ml of the peptide-antigens (Ag) used to generate them (the C480-499 and the C491-523 peptides, respectively) before 
being used to label tissue sections from wild-type rats (r-WT), wild-type mice (m-WT) and EAAT3 knockout mice 
(mEAAT3-KO). The fact that the two EAAT3 antibodies label tissue devoid of EAAT3 shows that these antibodies cross-react 
with non-EAAT3 epitopes. Then, note that pre-adsorption with the peptide-antigens blocks the interaction with both the EAAT3 
and the non-EAAT3 epitopes. The anti-B12 (Ab#360) antibodies to EAAT2 were pre-absorbed overnight with C491-523 peptide 
and amounts as indicated. They were unaffected by the presence of EAAT3-peptides (as expected). Also note that the epitope 
cross-reacting with the anti-C491 antibodies is not uniformly distributed (see also Fig. 3). This shows that an antibody may be 
specific in one brain region and not in another depending on the distribution of cross-reacting molecules. Scale bar: 4 mm in r-
WT and 2 mm in  m-WT and m-EAAT3-KO. 
 
Similarly, the antibodies (in particular anti-B493 
and anti-B372) labeled heart tissue 
(cardiomyocytes) while the others only gave weak  
labeling unless used in high concentrations. Again, 
the use of multiple antibodies raised the suspicion 
that the labeling of cardiomyocytes with the anti-
B493 and anti-B372 might be due to cross-
reactivity. Other data (S. Holmseth and N.C. 
Danbolt, unpublished) show that the heart does not 
express EAAT2 (no detectable EAAT2-like uptake  
activity and the levels of EAAT2 mRNA are 
exceedingly low). In contrast, pre-adsorption of the 
anti-B493 antibodies blocked all labeling and gave a 
misleading impression.  
 
Antibodies to glutamate transporter 3 (EAAT3, 
slc1a1): Here we compared three of the 87 
antibodies we have made (Holmseth et al., 2005) to 
EAAT3 (anti-C491, anti-C480-tub and anti-C510). 
The anti-C480-tub antibodies ware produced by 
fractionation of an antiserum collected after 
immunization with a peptide representing EAAT3 
residues 480-499. These antibodies cross-reacted 
with tubulin while another fraction from the same 
serum was highly specific for EAAT3 (Ab#359; not 
shown here, but see Holmseth et al., 2005). All the 
antibodies gave rise to labeling in all brain regions  
in wild-type mice and rats, but anti-C491 and anti-
C480-tub also labeled sections from the EAAT3 
knockout mice (Fig. 2). The widespread labeling 
obtained with anti-C480-tub is consistent with the 
widespread distribution of tubulin. Also the anti-
C491 antibodies reacted with the knockout, but in 
this case the labeling pattern observed in sections 
from the knockout was not uniform. These 
antibodies labeled hippocampus CA1-3 and striatum 
strongly while neocortex and thalamus were 
virtually unlabeled. This illustrates that cross-
reactivity can be highly specific and limited to one 
tissue or region.  
 Pre-adsorption of the anti-C491 antibodies 
with the C491-523 peptide and pre-adsorption of the 
anti-C480-tub antibody with the C480-499 peptide 
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Figure 3: Antibody concentrations affect labeling intensities. Sections from wild-type (WT) and EAAT3-deficient mice (KO) 
were incubated with either anti-C491 (Ab#371) or anti-C510 (Ab#565) antibodies in concentrations as indicated. Note that anti-
C491 cross-react with something else in some regions (arrow heads: hippocampus and striatum). Also note that both antibodies 
give rise to labeling in all brain regions when used in high concentrations. Consequently, when adjusting labeling conditions 
(fixation, blocking, antibody concentrations, etc), it is usually possible to get labeling. The difficult part is to determine if the 
labeling represents the molecule under study or something else. Scale bar: 2 mm. 
 
  
eliminated all labeling, including labeling of cross-
reactive epitopes seen in the sections from the 
EAAT3-knockout mice (Fig. 2). Thus, the C480-499 
peptide representing EAAT3 blocked interaction 
between the anti-C480-tub antibodies and tubulin. 
Antibodies to EAAT2 were used as a positive  
 
 
 
control and were unaffected by the addition of 
EAAT3 peptides.  
 The immunoreactivity observed in EAAT3 
knockout tissue with anti-C491 antibodies raised the 
question of whether the knockout mice express 
some EAAT3 protein. This possibility could be 
ruled out because anti-C510 antibodies at 
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comparable concentrations did not show this pattern 
of labeling in sections from the EAAT3 knockout 
mice (Fig. 3). Figure 3 also illustrates how the 
labeling depends on the antibody concentrations. 
Without the negative control that the tissue from the 
EAAT3 knockout represents, it would have been 
difficult to discriminate non-specific labeling from 
that representing EAAT3.  
 
Antibodies to betaine-GABA transporter (BGT1, 
slc6a12): Our laboratory has made a number of 
antibodies also to this protein (27 antibody batches, 
14 synthetic peptides and 9 animals: S. Holmseth, 
Y. Zhou and N.C. Danbolt, unpublished). Here we 
selected one of these antibodies (anti-BGT599). 
4G), but not in BGT1 knockout mice (Figs. 4B and 
4I). Although this immunoreactivity represents 
BGT1 (Y. Zhou, S. Holmseth and N.C. Danbolt, 
unpublished), the most prominent signal obtained 
This particular antibody to BGT1 labeled tubules in 
the renal medulla in wild-type mice (Figs. 4A and 
with this antibody in kidneys was associated with 
the capillary endothelium, in particular the renal 
glomeruli in the cortex. Because this labeling was 
seen in both wild-type (Figs. 4A and 4C) and BGT1 
knockout mice (Figs. 4B and 4E), it is highly 
unlikely to represent BGT1. Further, the other 
BGT1 antibodies (not shown) did not label 
endothelium, but they did label medullary tubules. 
Nevertheless, addition of excess antigen (peptide) to 
anti-BGT599 led to complete loss of glomerular 
labeling (Fig. 4D and 4F), indicating that pre-
adsorption prevented association with both specific 
and non-specific epitopes. Also note that there is 
labeling in the cerebellum of both the wild-type 
(Fig. 4K) and the knockout (Fig. 4M) mice, but not 
after antigen pre-adsorption (Fig. 4L and 4N).  
 
The usefulness and limitations of Western blots 
Antibodies to BGT1: The anti-BGT1 antibodies 
were also tested on Western blots. Tissue was 
collected from both the outer renal medulla and the 
renal cortex of both wild-type and BGT1 knockout 
mice. As shown in the left panel of Fig. 5, the BGT1 
band was the predominant band (asterisk) and was 
only observed in the water insoluble fraction from 
the outer medulla from wild-type mice (Lane 4). 
Thus, the antibodies appeared to be specific, 
although some lower molecular mass species were 
labeled in all lanes containing water insoluble 
proteins (Lanes 2, 4, 6 and 8) and there was more 
background in lanes from the cortex (Lanes 5-8) 
than from the medulla (Lanes 1-4). Consequently, 
this did not explain the labeling observed in the 
kidney sections (Fig. 4). There are major differences 
between sections and Western blots (solubilized 
molecules may have different conformations 
and are likely to be separated from their natural 
molecular neighbors, the smallest and the largest 
molecules are lost, and the three dimensional 
structure of the tissue is destroyed). But in addition 
to this, the tissue used for immunocytochemistry 
was fixed for one hour in  4 % formaldehyde and 
then blocked with 10 % newborn calf serum prior to 
incubation with the antibodies, while the blots were 
not exposed to aldehydes and were blocked with 1 
% bovine serum albumin. To get some assessment 
of whether fixation and blocking account for these 
differences, blots were fixed in 4 % formaldehyde 
for one hour prior to immunolabeling. As shown in 
Fig. 5 (middle and right panels), a substantial 
increase in non-BGT1 labeling was observed in this 
condition. This cross-reactivity was so strong that 
the BGT1 band was not visible when 1 % bovine 
serum albumin was used as blocking agent (Fig. 5, 
middle panel). The stronger blocking (10 % 
newborn calf serum) used for immunocytochemistry 
reduced unwanted labeling sufficiently to allow  
identification of the BGT1 band (Fig. 5, Lane 4 
asterisk). Nevertheless, even with this blocking 
condition, a strongly labeled band (arrow head) 
appeared in the renal cortex from both wild-type 
(Lanes 5 and 6) and BGT1 knockout mice (Lanes 7 
and 8). This labeling was strong enough to raise 
legitimate speculation of whether this is the 
molecular species that give rise to the glomerular  
labeling in the sections (Fig. 4). 
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Figure 4: Pre-adsorption test gives a false sense of specificity also in the case of the anti-BGT599 (Ab#323) antibodies to BGT1. 
The antibodies (3 g/ml) label the outer renal medulla (om) stronger in wild-type mice (A and G) than in BGT1 knockout mice (B 
and I). This is the labeling that truly represents BGT1 (Zhou et al. 2011), but note labeled glomeruli (g) in the renal cortex (cx) 
from both wild-type (A, C) and knockout (B, E) mice. This means that the antibody cross-reacts with something present in 
capillaries in glomeruli and also elsewhere in the kidney as seen in the medulla (I, arrowheads). Also note that there is labeling in 
the cerebellar granule cell layer (gr) both in wild-type (K) and knockout mice (M). Panels D, H, L, F, J and N show that virtually 
all labeling, regardless of whether it represents BGT1 or not, is abolished if the antibodies are pre-adsorbed with the peptide (1 
mg/ml BGT599-614) to which they have been raised and affinity purified. The only remaining labeling (*) seen in panels L and N 
is due to reactivity of the secondary antibody. Fixative: 4 % formaldehyde without glutaraldehyde. Scale bars: A and B, 200 μm; 
C-N, 20 μm.
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Figure 5: Fixation creates new epitopes cross-reacting with the anti-BGT1 antibodies. Tissue from the renal medulla (Lanes 1-4) 
and cortex (Lanes 5-8) from both BGT1 knockout (Lanes 1, 2, 5 and 6) and wild-type (Lanes 3, 4, 7 and 8) mice was 
homogenized in water to yield water soluble (Lanes 1, 3, 5 and 7) and water insoluble fractions containing membrane proteins 
(Lanes 2, 4, 6 and 8). Three identical blots were made. Before development with the anti-BGT1 antibodies (Ab#323; 0.5 g/ml), 
two of the blots (as indicated: middle and right) were incubated (1h, room temperature) in the same fixative as was used to fix the 
tissue for immunocytochemistry (Fig. 4). The unfixed (left) and one of the fixed blots (middle) were developed using 1 % bovine 
serum albumin (BSA) as blocking agent, while the last was blocked with the same blocking agent as was used for 
immunocytochemistry (Fig. 4: 10 % newborn calf serum (NCS)). The band representing the BGT1 protein is indicated (Lane 4; 
asterisk). Note that many extra bands are seen after fixation (arrowheads). 
 
 
Antibodies to EAAT3: The anti-C491 antibodies 
recognized EAAT3 in brain extracts from both rat 
and wild-type mice, but not from EAAT3 knockout 
mice (Fig. 6A). This antibody looked specific when 
tested on Western blots and the blots therefore did 
not explain the cross-reactivity observed in sections 
(Figs. 2 and 3). Brains from wild-type and EAAT3 
knockout mice were dissected to enable blotting 
(Fig. 6CD) of hippocampus, neocortex, and 
cerebellum separately. Further, 10-20 % gradient 
gels were used to detect more of the smaller 
proteins. Two identical blots were made. Fixation of 
one of the blots (6D) showed that fixation enhanced 
binding to cross-reactive epitopes, but there was in 
this case no clear correlation between blots and 
sections. While the immunocytochemistry showed 
particularly strong cross-reactivity in the 
hippocampus, the blots did not reveal any 
hippocampus specific cross-reactive molecular  
 
species.   
 The anti-C480-tub antibodies (Fig. 6B) 
recognized a band (arrowhead) with slightly lower 
apparent molecular mass than EAAT3. This band 
was present in all the three lanes, including the one 
with the extract from the EAAT3 knockout, in 
agreement with the conclusion (Holmseth et al., 
2005) that this antibody recognizes tubulin. This 
band became visible after very short development 
times, while longer development times were needed 
to visualize EAAT3. The arrow in Fig. 6B points to 
the location of EAAT3. The reason is that tubulin is 
one of the most abundant proteins in the brain 
(Shelanski et al., 1973) while EAAT3 represents 
less than 0.01 % (Danbolt et al., 2006). Thus, the 
labeling of this blot matches the labeling seen in the 
sections.  
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Figure 6: Immunoblots showing the specificity of two 
different antibodies to EAAT3.  (A, C and D) anti-C491 
(Ab#371; 0.5 g/ml) and (B) Anti-C480-tub (Ab#547; 1 
μg/ml). Each lane contained 20 μg of SDS-extracted whole 
hippocampal tissue proteins obtained from wild-type Wistar 
rats (Lane 1), wild-type mice (Lane 2) and EAAT3 knockout 
mice (Lane 3). Note that the anti-C491 antibodies clearly 
visualize the EAAT3 protein (arrow) in extracts from wild-
type mice and rats (Panel A, Lanes 1 and 2). There is no 
labeling of proteins from the EAAT3 knockout (Panel A, Lane 
3). In contrast, the anti-C480-tub antibodies label the EAAT3-
band weakly (too weak to be easily seen on this blot) (arrow), 
but they label another protein (tubulin) strongly (arrowhead). 
This protein is present in very high concentrations in all the 
three protein extracts (Panel B, Lanes 1, 2 and 3). Note that the 
labeling has reached saturation. The identities of the lower 
bands have not been determined, but may represent partly 
proteolysed tubulin.  Panels C and D represent two identical 
blots of 10-20 % gradient gels. Gradient gels were used to 
detect also low molecular mass proteins. The blot in C is 
unfixed while the blot in D was fixed before incubation with 
the antibodies The blots contain extracts from mouse 
hippocampus (HC, whole tissue), mouse neocortex (WS, water 
soluble; MP, membrane pellet), and mouse cerebellum (WS, 
water soluble; MP, membrane pellet) separately. 
 
Testing of antibodies to EAAT2: As shown (Fig. 7) 
all of the antibodies used in figure 1 recognized 
EAAT2 in brains from wild-type mice. There was 
strong labeling of a band at around 70 kDa (Lane 1), 
and this band is not seen in brain samples from the 
EAAT2-knockout mice (Lane 2). The anti-B493 
antibodies also labeled a band with lower molecular 
mass (below the 45 kDa marker) fairly strongly. 
This may explain why this antibody gave some 
labeling of brain tissue from the knockout mice. The 
rest of the antibodies, however, look highly specific 
on blots of forebrain (Fig. 7) and cerebellum (not 
shown). Thus, in the case of anti-B2, anti-B12, anti-
B493 and anti-B563 there are good correlations 
between the labeling seen on blots and in sections. 
These four antibodies did not give much labeling in 
sections from the knockout mice (Fig. 1). In 
contrast, although the anti-B372 antibodies looked 
highly specific on blots, they still labeled tissue 
from the knockout mice strongly (Fig. 1). Further, 
note that anti-B493 and the anti-B2 antibodies 
labeled bands (Fig. 7, arrowheads) that could be 
mistaken for EAAT2 in the heart samples. The 
presence of these bands in the sample from the 
knockout, and the fact that the other antibodies did 
not label them, proved that this was not EAAT2. In 
contrast, pre-adsorbing the anti-B493 with the 
peptide blocked the labeling giving the mistaken 
impression that the labeling was specific for 
EAAT2. Fixing the blots before immunolabeling 
gave more information. The labeling obtained with 
the anti-B12 and the anti-B563 antibodies appeared 
virtually unaffected. However, fixation created 
several epitopes that cross-reacted with the anti-
B493, the anti-B2 and the anti-B372. This may, at 
least in part, explain why anti-B493 and anti-B372 
labeled cardiomyocytes 
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Figure 7: Forebrain (Lanes 1 and 2) and heart (Lanes 3 and 4) tissue from wild-type (Lanes 1 and 3) and EAAT2 knockout 
(Lanes 2 and 4) mice were solubilized and immunoblotted with the same antibodies were as used in Fig. 1. Fourteen identical 
blots were prepared. Half of them were fixed (3 h, 4 % formaldehyde and 0.1 % glutaraldehyde in 0.1 M NaPi) before being 
developed with the antibodies as indicated. One of the antibodies, anti-B493 (Ab#95), were pre-adsorbed overnight with 10 μg/ml 
peptide-antigen (Ag). This low antigen concentration was sufficient to abolish both the labeling representing EAAT2 and the 
cross-reactivity seen on unfixed blots. Two of the antibodies (anti-B2 and anti-B493) label heart (arrowheads) at the same 
molecular mass as EAAT2 (Lane 1), but note that this band is also seen in the knockout (Lane 4). Also note that the anti-B2 
antibodies reacted better with the fixed EAAT2 than the unfixed protein, while other antibodies showed weaker reaction after blot 
fixation (not shown). Antibody concentrations: anti-B2 (Ab#48) 1 μg/ml; anti-B12 (Ab#360) 0.2 μg/ml; anti-B372 (Ab#63) 1 
μg/ml; anti-B493 (Ab#95) 0.2 μg/ml; anti-B563 (Ab#355) 0.2 μg/ml. The lanes contained either 5 μg of forebrain protein or 20 
μg heart protein extracted with SDS.
  
(Fig. 1).  But also note that the cross-reaction 
observed with the anti-B2 antibodies on blots of 
heart proteins did not occur in sections as the latter 
were unlabeled (Fig. 1).  
 
DISCUSSION 
Burry (2011) introduced a new classification of 
immunocytochemical controls. According to this 
system there are three groups of controls: primary 
antibody controls, secondary antibody controls and 
label controls. The focus of the present study is 
primary antibody controls which are usually the 
most difficult ones.  
 
Specificity and sensitivity 
The labeling is sensitive if low concentrations of the 
antibodies give rise to labeling, and it is specific if 
the antibodies bind only to the target antigen. At low 
antibody concentrations, only the antigens that have 
the highest affinities will be labeled. Antigens 
interacting with lower affinities will be labeled at 
higher antibody concentrations. Thus, if the antigen 
of interest binds the antibodies with much higher 
affinity than other antigens, then the labeling will be 
specific at low concentrations. One problem is that 
cross-reactive antigens can sometimes bind with 
high affinity as illustrated here and by others (e.g. 
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Josephsen et al., 1999; Dolman et al., 2004; 
Holmseth et al., 2005; Lorincz and Nusser, 2008). 
Another problem is that illustrated in figure 3. 
Labeling can usually be obtained by adjusting the 
assay conditions to increase sensitivity. The labeling 
of sections from knockout mice mimics situations 
where a protein is not present or present below 
detection limit. It is not easy to distinguish a true 
positive signal from a false positive signal. Several 
antibodies to the same protein can help, but as 
shown with the selected antibodies to EAAT2 (Fig. 
1), several antibodies may have the same reactivity. 
In particular, we have frequently observed cross-
reactivity with mitochondria, post-synaptic 
densities, cell nuclei and the cerebellar molecular 
layer. Thus, immunocytochemical labeling is not in 
itself a proof of expression. Consequently, to avoid 
chasing "ghosts" it is imperative to use other 
methods (e.g. immunoblots, mRNA quantifications, 
enzyme activity or other relevant parameters) to 
verify that the target antigen is indeed present at 
physiological relevant concentrations in the tissue 
under study.  
 
The psychology 
The start of an immunocytochemistry project is 
usually an intriguing hypothesis predicting the 
presence of the protein. And if beautiful images are 
obtained, everyone gets optimistic. The labeling 
observed in the sections from the knockout mice 
shown here could easily have been interpreted as 
true labeling. And in the case of the series of 
EAAT2 antibodies, the weaker labeling with the 
anti-B2 and anti-B563 antibodies could have been 
disregarded by arguing that these are splice variant 
specific antibodies. This argument might even have 
made the hypothesis more interesting. The pre-
adsorption test would have supported the exciting 
interpretation. Thus, the pre-adsorption test would 
have been dangerously misleading.   
 
Why it is difficult to verify labeling specificity 
Labeling is assumed to be specific when all control 
experiments have failed to detect cross-reactivity. 
This perspective must be kept in mind when 
designing and interpreting control experiments. As 
pointed out (Saper and Sawchenko, 2003; Holmseth 
et al., 2005), an antibody molecule is not  a "magic 
bullet" with absolute specificity, but a protein 
molecule which recognizes the antigen much like a 
receptor protein recognizes the ligand or an enzyme 
recognizes the substrate. Antibodies can adhere to 
other molecules, according to their respective 
concentrations and affinities (Rhodes and Trimmer, 
2006; Fritschy, 2008). A good antibody binds to the 
desired target with high affinity, allowing it to be 
used at a concentration well below the concentration 
where it starts to bind to other targets. It should be 
recalled how medicinal chemists are able to develop 
new molecules that bind to the same receptor as 
endogenous ligand in spite of having a very different 
chemical structure. From this perspective it is not 
surprising that antibodies often cross-react with 
seemingly unrelated molecules. It should also be 
taken into account that tissue processing (post 
mortem delay, fixation, embedding and antigen 
retrieval) chemically modifies the tissue, leading to 
the creation and elimination of epitopes (e.g. 
Josephsen et al., 1999).  
 
Poly-reactive antibodies are common 
Since we made the first antibodies to a glutamate 
transporter (Danbolt et al., 1992), our laboratory has 
produced about one thousand different antibodies, 
only a minority of which lacked non-specific 
labeling. Even after affinity purification, most 
antibodies obtained from immunizing rabbits still 
displayed some degree of cross-reactivity with 
unrelated proteins (Holmseth et al., 2005). Our 
impression is that this problem gets worse if the 
animals are given strong adjuvants that trigger tissue 
damage around the injection sites, possibly because 
this may contribute to production of auto-antibodies, 
e.g. lupus erythematosus-like anti-DNA antibodies. 
Many of these antibodies do not only bind to DNA, 
but also to peptide sequences (Sibille et al., 1997; 
James et al., 1999) and may even cross-react with 
the glutamate receptor subtype NR2 (DeGiorgio et 
al., 2001).  
 Thus, it is important to realize that cross-
reactivity does not have to be due to the presence of 
contaminating antibodies, but can be due to the 
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antigen recognizing antibodies themselves, as shown 
here with the anti-C480-tub antibodies and shown 
previously with monoclonal antibodies (Danbolt et 
al., 1998). During the process of generating 
monoclonal antibodies to the EAAT2, several 
monoclonal antibodies turned out to recognize 
multiple bands on Western blots.  
 
The correct use of the pre-adsorption control 
In the early days of immunocytochemistry, only 
crude sera were used to label sections. A serum 
contains a huge number of different antibodies. 
Most of these are produced by the host animal so 
that it can protect itself against infections. 
Experimental immunizations with the antigen of 
interest, will cause changes in the antibody 
expression profile and, hopefully, but not 
necessarily, to production of new antibodies 
specifically recognizing the antigen to be studied. 
The content of total IgG in rabbit sera is about 10 
mg/ml, but only a small fraction of these (may be a 
couple of percent in a good antiserum) will be 
antibodies to the injected antigen. Therefore, when a 
serum is used for labeling of tissue sections, it is 
important to determine if the labeling is due to 
antibodies directed toward the antigen or to other 
antibodies. A first indication can be obtained by 
comparing serum collected after immunization 
(immune-serum) with serum collected before 
immunization (pre-immune serum). This tells if the 
immunoreactivity of the serum was there before 
immunization started or came after the 
immunization (and therefore may be a consequence 
of it), but this does not tell if the labeling is due to 
antibodies to the target antigen or to antibodies to 
other substances (e.g. components of the adjuvant 
used to enhance the immuneresponse). This is where 
the pre-adsorption control comes in. If addition of 
the target antigen to the serum prevents the serum 
from labeling the sections, then it follows that the 
labeling is due to those antibodies that are able to 
bind the added antigen. It is important to note that 
this does not test if the antibodies also can bind 
other antigens. For example, assume that the 
purpose of an experiment is to localize antigen X, 
and that the available antiserum contains both 
antibodies to this antigen and multiple different 
antibodies to other unknown antigens (collectively 
referred to as non-X). Then assume that the 
antibodies to X cross-react with another non-X 
antigen (Y). If pre-adsorption with X does not block 
the labeling, then the labeling cannot represent X 
because it must be due to non-anti-X antibodies. On 
the other hand, if addition of X does indeed block all 
labeling, then the labeling must be due to the anti-X 
antibodies and not to any of the other antibodies to 
non-X. This would be a good sign in that this means 
that the labeling is due to anti-X antibodies. 
However, the anti-X antibodies are in this case also 
able to bind Y, and pre-adsorption with X will block 
labeling to both X and Y. Thus, the pre-adsorption 
will tell that anti-X is responsible, but not if anti-X 
binds to X or to Y or to both in the sections. 
 Thus, when crude sera are being used, then 
the pre-adsorption test does add valuable 
information. If the antigen can be readily obtained in 
pure form, and in particular if tissue from knockout 
animals are unavailable, this test should be carried 
out. A common situation today, however, is to work 
with antibodies that are already selected for their 
ability to bind to the antigen (monoclonal or affinity 
purified polyclonal antibodies). In this situation, we 
do not need the pre-adsorption test to tell us that the 
antibodies we are working with have the ability to 
interact with the antigen. Possible binding of the 
antibodies via a mechanism not involving antigen 
binding sites (e.g. by inadequate blocking of 
unspecific binding or presence of antibody binding 
molecules such as bacteria expressing protein A) is 
likely to be revealed by using normal antibodies 
(e.g. pre-immune antibodies) so the pre-adsorption 
test is not relevant for that either. 
 
Notes on immunoblots 
As explained above, the antibodies shown here have 
not been randomly selected, but been selected to 
illustrate a number of points. Together they may 
give the impression that there is poor correlation 
between labeling of immunoblots and sections. But 
that is not the message we want to send. Our 
experience with immunoblots is that they are 
informative. They are also relatively inexpensive. If 
 15
antibodies look specific on blots, then they are often 
also specific in sections. Nevertheless, exceptions 
like those shown here are so common that 
immunoblots should be supplemented with other 
tests whenever possible.  
 When interpreting immunoblots, it is 
important to keep in mind that one band may 
contain more than one protein. The anti-B493 
antibodies (Fig. 7) illustrate this point. A weak non-
EAAT2 band is present in Lane 2 (brain from the 
knockout mice) as well as in the heart samples 
(arrowhead). The most likely interpretation is 
therefore that the EAAT2 band in lane 1 is a mixture 
of (mostly) EAAT2 and this other molecular 
species.  
 Another point to keep in mind is that one 
protein may give rise to several bands by a variety 
of mechanisms (e.g. partial proteolysis, post 
translational modifications, or oligomerization). 
Extra bands are frequently observed, but it is often 
hard to determine the identity of them. In the present 
study this is fairly straight forward because samples 
from knockout mice were run as controls, and 
because we have access to several antibodies to each 
protein. Bands present in the samples from the 
knockout mice must represent cross-reacting 
molecules. Further, if antibodies to several parts of 
the same protein are available [in our case we have 
antibodies to nine different regions of EAAT2 as 
well as to the various splice variants (Holmseth et 
al., 2005, 2009)] then extra bands will be labeled by 
several antibodies if they indeed represent the same 
protein. However, as we have pointed out above, 
bands representing cross-reactivity are so common 
that our advice is to assume that extra bands 
represent cross-reactivity unless positive evidence 
can be provided. 
 
Genetically modified tissue 
As pointed out by many (e.g. Holmseth et al., 2006; 
Burry, 2011), not even genetically modified 
organisms are perfect specificity controls. For 
instance, when a gene is deleted, then this may 
affect expression of other genes. Cross-reactive 
molecules may be down-regulated or up-regulated. 
Nevertheless, as illustrated here, knockout animals 
do represent very powerful controls. The main 
problem is their availability and the fact that most of 
them are mice while most immunocytochemistry is 
done on rat and human tissue. Another problem can 
be other genes containing the same sequence, or 
residual expression of the deleted gene unless the 
deleted sequence includes the part containing the 
epitope or care has been taken to carry out the 
deletion in such way that it causes a shift of the 
reading frame. However, if an antibody gives rise to 
labeling in knockout tissue, then this should not be 
taken lightly. Unless residual expression can be 
proven, then it is our experience that the most likely 
explanation is unwanted reactivity of the antibodies. 
We have tested a fairly large number of antibodies 
on tissue from seven different knockout lines (those 
shown here and unpublished data from antibodies to 
slc1a3, slc6a1, slc6a11 and sc6a13).   
 Another problem with transgenic animals is 
the costs limiting the number of laboratories that can 
afford it. But although testing on tissue from 
knockout animals is expensive in the short term, this 
may be the cheapest for the society as a whole in the 
long run because the most expensive is to work on a 
project for long time and then discover that the 
labeling is insufficiently specific or even publish 
erroneous data. Wen incorrect data are published, 
correction is even more costly. 
 
Conclusions 
The primary focus of this study has been to evaluate 
the pre-adsorption test. We rediscover and illustrate 
that this test is not a specificity test in the true sense, 
but test to identify the population of antibodies that 
is responsible for the labeling. This test does not tell 
if the observed labeling represents a specific 
visualization of the antigen under study or if it is due 
to cross-reaction with other molecules. This is old 
knowledge and has been discussed, albeit not 
illustrated, in several publications (e.g. Swaab et al., 
1977; Pool and Buijs, 1988; Burry, 2000; Holmseth 
et al., 2005; Fritschy, 2008; Burry, 2011). Despite 
this, the pre-adsorption test is still regarded by many 
as an obligate control for the verification of 
immunocytochemical labeling - even labeling 
obtained with monoclonal and affinity purified 
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antibodies. As shown here the pre-adsorption test 
can give a misleading impression of specificity. 
Compounding this problem, it is often costly to 
obtain enough free antigen to perform the test, 
diverting time and resources from more definitive 
experiments.  
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ABBREVIATIONS 
The abbreviations used are: BSA, bovine serum albumin; CHAPS, 3-[(3-cholamido 
propyl)dimethylammonio]-1-propanesulphonate; EAAC1, glutamate transporter subtype 3; 
EAAT, Excitatory amino acid transporter (= glutamate transporter); EDTA, sodium 
ethylenediamine tetraacetate; GABA, aminobutyric acid; GFAP; glial fibrillary acidic 
protein; GLAST, glutamate transporter subtype 1; GLT1, glutamate transporter subtype 2; 
HEPES, 4-(2-hydroxyethyl)-1- piperazineethanesulfonic acid; MBP, myelin basic protein; 
MK-801, dizocilpine; NBQX, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline; 
PMSF, phenylmethanesulfonyl fluoride; Rb, rabbit; SDS, sodium dodecyl sulfate; SDS-
PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; Sh, sheep; TBOA; DL-
threo--benzyloxyaspartate; TBST, Tris-buffered saline with 0.1% Triton X-100; TTX, 
tetrodotoxin; SR95531, 6-imino-3-(4-methoxyphenyl)-1(6H)-pyridazinebutanoic acid HBr. 
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ABSTRACT 
GLAST and GLT1 are the most abundant glutamate transporters in the mammalian brain, and 
are essential for harnessing glutamate. The roles of the other glutamate transporters are 
poorly understood. In particular, studies of EAAC1, the predominant neuronal transporter, 
have arrived at different conclusions in part because the density of EAAC1 is unknown and 
because of variable specificity of available antibodies. We isolated EAAC1 protein, and used 
the pure protein in known amounts as standards during immunoblotting to determine the 
concentration of EAAC1 in the hippocampus of young adult Wistar rats. The concentration 
was about 0.013 mg/gm tissue (about 130 molecules μm-3) and thus 100 times lower than that 
of GLT1. The EAAC1 concentration increased from E18 to P14 and then decreased by a 
factor of three by adulthood. Using EAAC1 knockout mice as negative controls to establish 
antibody specificity, we show that EAAC1 is present in somata and dendrites of all 
hippocampal neurons and not in axon-terminals, astrocytes or oligodendrocytes. If all 
EAAC1 transporters were trafficked to the membrane, the average density would be 
approximately 90 μm-2 assuming a surface density of dendrites and spines of 1.5 μm2/μm3. 
The effective number is probably lower because most of EAAC1 is intracellular. Photolysis 
of MNI-D-aspartate failed to elicit EAAC1-mediated transporter currents in CA1 pyramidal 
neurons. D-aspartate uptake was not detected electron microscopically in spines. This and the 
low glutamate uptake activity in the GLT1 knockout mice suggest that EAAC1 is involved in 
neuronal metabolism, rather than rapid clearance of synaptically released glutamate.  
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INTRODUCTION 
The extracellular levels of the neurotransmitter glutamate have to be tightly controlled to 
ensure high fidelity in synaptic transmission and to prevent excitotoxicity. This is 
accomplished by cellular uptake (Danbolt, 2001). The most important glutamate transporter 
subtypes are GLAST (EAAT1) and GLT1 (EAAT2). The roles of the third subtype, EAAC1 
(EAAT3, slc1a1), is still debated. Some data suggest that EAAC1 is primarily involved in 
metabolic processes. For instance, immunisolation of transport activity (Haugeto et al., 
1996), deletion of the GLT1 (slc1a2) gene (Tanaka et al., 1997; Bergles and Jahr, 1997; 
Bergles and Jahr, 1998; Sun et al., 2011), and the mild phenotype of EAAC1-deficient mice 
(Peghini et al., 1997) indicate that EAAC1-mediated glutamate uptake is negligible compared 
to that of GLT1. EAAC1-deficient mice suffer from dicarboxylic aminoaciduria and from 
premature ageing (Aoyama et al., 2006; Chen and Swanson, 2003; Berman et al., 2011), but 
do not exhibit overt CNS phenotypes suggestive of impaired glutamatergic or GABAergic 
signaling. Observations of humans with defective EAAC1 are in line with this view (Bailey 
et al., 2011). On the other hand, antisense knockdown indicates that the EAAC1 subtype 
accounts for about 40 % of the glutamate uptake activity in the hippocampus (Rothstein et 
al., 1996), and high resolution immunolabeling studies (He et al., 2000; He et al., 2001) have 
concluded that EAAC1 is present in dendritic shafts and in spines surrounding active zones 
as well as in terminals. At hippocampal synapses in EAAC1-deficient mice, glutamate 
transporter currents in astrocytes decay more rapidly, suggesting that the predominant action 
of EAAC1 is to buffer, rather than rapidly transport glutamate (Scimemi et al., 2009). This 
buffering may increase the probability of glutamate capture by GLAST and GLT1 that are 
present at high densities in astrocytic processes (Lehre and Danbolt, 1998). By this 
mechanism, EAAC1 could limit activation of perisynaptic NMDA receptors and increase the 
threshold for induction of long term potentiation (Scimemi et al., 2009). Further, functional 
studies suggest that EAAC1 is also present in GABAergic nerve terminals, where it may help 
maintain GABA levels by providing glutamate for GABA synthesis (Sepkuty et al., 2002; 
Mathews and Diamond, 2003; Stafford et al., 2010). Several of these studies are of excellent 
quality and it is hard to judge who is right. This is further complicated by the fact that 
different model systems have different limitations and that EAAC1 can be dramatically 
upregulated (Ross et al., 2011). Thus, the role of EAAC1 may differ between preparations. 
To resolve this conundrum, we have quantified the amounts of EAAC1 protein relative to 
GLT1 protein, and we show that EAAC1 is approximately 100-fold less abundant than GLT1 
in the young adult rat hippocampus. Further, we validated the specificity of EAAC1 
antibodies using tissue from EAAC1-deficient mice, and determined the EAAC1 distribution 
immunocytochemically. We find EAAC1 in dendrites of all cells identified as neurons, but 
not in axons, terminals, oligodendrocytes or astrocytes. The data support the hypothesis that 
EAAC1 plays a role in neuronal metabolism rather than neurotransmission.  
 
 
 
 
MATERIALS AND METHODS 
Materials 
Sodium dodecyl sulfate (SDS) of high purity (>99 % C12 alkyl sulfate), 
bis(sulfosuccinimidyl)suberate, SuperSignal West Dura® were from Pierce (Rockford, IL, 
USA) and electrophoresis equipment were from Hoefer Scientific Instruments (San 
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Francisco, CA, USA). N,N'-methylene-bisacrylamide, acrylamide, ammonium persulfate, 
TEMED and alkaline phosphatase substrates (nitroblue tetrazolium and 
5-bromo-4-chloro-3-indolyl phosphate) were from Promega (Madison, WI, USA). Protein 
A-Sepharose Fast Flow and Sephadex G-50 fine were from Pharmacia (Uppsala, Sweden). 
Molecular mass markers for SDS-polyacrylamide gel electrophoresis (SDS-PAGE), ECL-
films and Nitrocellulose sheets (0.22 m pores, 100 % nitrocellulose) were from Amersham 
(Buckinghamshire, UK). Paraformaldehyde and glutaraldehyde EM grade were from TAAB 
(Reading, UK). Lowicryl HM20 was from Electron Microscopy Sciences (Fort Washington, 
PA, USA). Bovine serum albumin (BSA), 3-[(3-cholamido-propyl) 
dimethylammonio]-1-propanesulphonate (CHAPS), dimethyl suberimidate, dithiotreitol, 
sodium ethylenediamine tetraacetate (EDTA), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), human serum albumin, phenylmethanesulfonyl fluoride (PMSF), Trizma base, 
Trisma-HCl, Triton X-100 and wheat germ agglutinin were obtained from Sigma (St. Louis, 
MO, USA). Wheat germ agglutinin was immobilized on agarose as described previously 
(Danbolt et al., 1992). Pure EAAT2 glutamate transporter protein was from the same batches 
as previously produced (Lehre and Danbolt, 1998).  
 
Antibodies 
Anti-peptide antibodies against glutamate transporters were from the same batches as 
described previously. The batch numbers are given below together with reference: The anti-
GLAST antibodies were the rabbit anti-A522 antibody (Ab#141; Lehre et al., 1995) and a 
mouse monoclonal anti-GLAST antibody (lot 124102; NCL-EAAT1; Novocastra 
Laboratories, Newcastle, UK; Banner et al., 2002). Both of these were directed to a peptide 
(PYQLIAQDNEPEKPVADSET-amide) representing residues 522-541 of rat GLAST 
(Storck et al., 1992). The anti-GLT1 antibodies were the monoclonal 9C4 antibody (Ab#531; 
Levy et al., 1993), the anti-B12 (Ab#360; Holmseth et al., 2005) to residues 12-26 of rat 
GLT1 (KQVEVRMHDSHLSSE-amide; Pines et al., 1992) and a monoclonal antibody NCL-
EAAT2 (lot 118003; Novocastra Laboratories, Newcastle, UK). Three synthetic peptides 
representing parts of EAAC1 (Kanai and Hediger, 1992; Bjørås et al., 1996) were used to 
produce the anti-EAAC1 antibodies used in the present report: C479 
(IVNPFALEPTILDNEDSDTK-amide), C491 
(CLDNEDSDTKKSYVNGGFSVDKSDTISFTQTSQF-free acid) and C510 
(VDKSDTISFTQTSQF-free acid). The rabbit antibodies to the C479 peptide (anti-C479; 
Ab#359) cross-reacted with tubulin and were therefore absorbed against immobilized tubulin 
before being used in the present study (Holmseth et al., 2005). The anti-C491 antibodies were 
from several different batches (Ab#237, Ab#236, Ab#371 and Ab#555) and have also been 
described (Holmseth, Dehnes, et al. 2006 #14000}). The anti-C510 antibodies were both 
from rabbit (Ab#126; Haugeto et al., 1996) and from sheep (Ab#340; Holmseth, Dehnes, et 
al. 2006 #14000}). The latter batch was further purified by passing it through a column with 
aldehyde treated bacterial proteins to remove unwanted antibodies (Danbolt et al., 1998). The 
antibodies that did not stick to the column were highly specific (Ab#565; Holmseth et al., 
2011). Anti-glutamine synthetase (MAB 302) was from Chemicon (Temecula, CA, USA), 
Anti-NG2 (sc-20162) was from Santa-Cruz Biotechnology (Santa Cruz, CA, USA), anti-
myelin basic protein (MBP) and anti-CNPase were Sternberger Monoclonals (Lutherville, 
MD, USA). Anti-VGLUT1 (clone 317D5) was from SYSY (Goettingen, Germany). Anti-
parvalbumin (P3088, lot 30K4824), anti-glial fibrillary acid protein (G3893, lot 082K4834), 
anti-glutamin synthetase (G2781, lot 061K4811), anti-synaptophysin (S5768), anti-GAD 
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(G1166, clone GAD-6), alkaline phosphatase- and peroxidase-conjugated monoclonal 
antibodies to mouse, rabbit and sheep IgG (A5187, A9452, A2179, A2556, A9044 and 
A1949) were from Sigma-Aldrich (St. Louis, MO, USA). Biotinylated anti-rabbit, anti-sheep 
and anti-mouse immunoglobulins, streptavidin-biotinylated horseradish peroxidase complex, 
and colloidal gold labeled anti-rabbit and anti-mouse immunoglubulins were from Amersham 
(Buckinghamshire, UK). Alexa fluor goat anti-rabbit 555, goat anti-mouse 488 and donkey 
anti-sheep 555 were from Molecular probes (Eugene, OR, USA). Other reagents were 
obtained from Fluka (Buchs, Switzerland). The fluorescein Lotus tetragonolobus lectin (FL-
1321, lot W0909) was from Vector Laboratories (Burlingame, CA, USA). 
 
Animals 
All animal experimentation was carried out in accordance with the National Institute of 
Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80 23) 
revised 1996 and the European Communities Council Directive of 24 November 1986 
(86/609/EEC). Formal approval to conduct the experiments described was obtained from the 
animal subjects review board of our institutions. Care was taken to avoid suffering and 
minimize the number of animals used. Adult male Wistar rats (9-12 weeks old as indicated) 
and C57Black/6 (3 weeks old) obtained from B&K Universal (Sollentuna, Sweden) were 
kept in the animal facility at the Institute of Basic Medical Sciences. Brain tissue for 
immunocytochemistry was obtained from rats that had been killed by injection of 
pentobarbital and fixed by cardiac perfusion as described (Danbolt et al., 1998). The 
generation of mice lacking EAAC1 and their genotyping, have been described in detail 
previously (Peghini et al., 1997). Experiments were carried out on EAAC1 wild-type and 
knockout mice (3-4 weeks old). Animals used for electrophysiology recordings were 12-17 
day-old Sprague-Dawley rats or mice.  
 
Electrophoresis and blotting 
SDS-PAGE was performed as described before (Lehre et al., 1995) with separating gels 
consisting of 7.5 or 10 % acrylamide, or with 4-20 % gradient gels. The molecular mass 
markers were used in non-reduced form. After electrophoresis the proteins were either silver 
stained or electroblotted onto nitrocellulose membranes. Because the purpose of the 
immunoblotting was to maximize the probability of detecting possible unwanted 
immunoreactivity towards non-EAAC1-proteins, the samples were prepared by 
homogenizing whole tissue directly in SDS so that the blots would contain as many of the 
tissue antigens as possible (for discussion of antibody specificity and testing see Holmseth et 
al., 2005).  
 Qualitative immunolabeling of blots (Fig. 1) was done using alkaline phosphatase 
conjugated secondary antibodies exactly as described previously (Lehre et al., 1995). This 
detection system has low contrast and is therefore suitable for detection of cross-reactivity. 
As shown (Fig. 1A-C), the antibodies used in this study labeled one weak, but relatively 
broad fuzzy band at around 70 kDa on immunoblots of fresh tissue from brain and kidney 
directly solubilized in SDS. Some weak bands representing non-EAAC1 proteins were also 
observed (e.g. Fig. 1A, strip 1), but the band representing EAAC1 was absent on blots 
prepared from tissue from EAAC1-deficient mice (Fig. 1D). This implied that the 
immunolabeling of this band could be used as a measure of the amount of EAAC1.  
 
Immunoaffinity purification of EAAC1 from rat kidney 
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Antibodies (0.5 mg anti-C491; Ab#236 or Ab#555) were immobilized on protein A-
Sepharose Fast Flow (0.5 ml) and covalently linked using dimethyl suberimidate as described 
previously (Danbolt et al., 1992). EAAC1 protein was purified three times (Table 1) using 
the following procedure: 20 kidneys (approximately 3 g protein) were freshly dissected from 
Wistar rats and homogenized in 10 volumes of ice-cold hypotone buffer (5 mM EDTA, 1 
mM PMSF) using a Polytron7 PT1200 homogenizer followed by treatment in a Dounce 
glass-glass homogenizer. The mixture was centrifuged (20 min, 39000 x g, 4 oC, Beckman 
JA20 rotor). The pellet was solubilized either in 10 volumes solubilization buffer (0.5 % 
lithium dodecyl sulfate, 45 mM Li-HEPES pH 7.5, 90 mM LiCl, 4.5 mM EDTA and 0.9 mM 
PMSF) or in 2 % cholate (Lehre and Danbolt, 1998) as indicated (Table 1). The mixture was 
sonicated (30 s, on ice, with a dr.Hilscher type UP 50H® sonicator) to reduce viscosity by 
breaking up DNA and then incubated (5 min on ice). When lithium dodecyl sulfate had been 
used, then Triton X-100 was added to a final concentration of 25-30 mg/ml in order to make 
the solution "antibody friendly". The resultant mixture was incubated (5 min on ice), and 
centrifuged (39,000 x g, 20 min, 4C, Beckman JA20 rotor). The supernatant was incubated 
end-over-end (90 – 270 min, 4C) with the immobilized antibodies (see above). The antibody 
beads were washed (3 x 6 min, 4C) with buffer (0.3 M NaCl, 20 mM CHAPS, 40 mM 
sodium phosphate buffer pH 7.4). Bound proteins were eluted (2 x 5 min, 4C) with low-pH 
buffer (0.15 M NaCl, 20 mM CHAPS, 0.32 M glycine-HCl, pH 2.0). The eluate was 
immediately neutralized by adding 1/10 volume 2 M Tris-HCl (pH 9). EDTA and PMSF 
were added to final concentrations of 5 and 1 mM, respectively. The eluate was then passed 
through a DEAE-cellulose column or a wheat germ agglutinin-agarose column as indicated 
(Table 1). The  wheat germ agglutinin-column was washed with 2 volumes washing buffer 
(20 mM CHAPS, 0.5 M NaCl and 20 mM sodium phosphate buffer pH 7.4) and bound 
proteins were eluted with NAG-buffer (0.200 mM N-acetylglucosamine, 20 mM CHAPS, 0.5 
M NaCl and 20 mM sodium phosphate buffer pH 7.4). Aliquots of the eluate destined for 
SDS-PAGE were mixed with SDS sample buffer containing 50 mM dithiothreitol and frozen. 
SDS was added to stop the irreversible aggregation of transporters that occurs in mild 
detergents (for a discussion of SDS-insoluble multimers of glutamate transporters see section 
7.4.2 in Danbolt, 2001) 
 Using this procedure highly purified rat kidney EAAC1 protein (Fig. 2, lanes 5-8) 
was obtained. There was no detectable leak of IgG from the affinity column. The IgG heavy 
chains give rise to a band just below that of EAAC1 (not shown). However, SDS-insoluble 
higher molecular mass aggregates formed during the purification procedure until the samples 
could be stabilized by the addition of SDS. This complicated protein measurement because 
non-aggregated and aggregated versions of the protein have different molecular masses and 
thereby have different blot transfer efficacies. Because only the monomer is seen on blots 
made from extracts prepared by direct solubilization of fresh tissue in SDS (Fig. 3A), only 
the monomer was useful as standard for immunoblotting. The concentrations of the monomer 
in the purified preparations of EAAC1 (Table 1) were determined densitometrically on silver 
stained polyacrylamide gels (Danbolt et al., 1990) using purified EAAT2 as a standard (Fig. 
2). EAAT2-protein was chosen because this is a closely related protein which thereby 
presumably reacts similarly with the silver stain, because it was available in sufficient 
quantities to allow precise determination of its concentrations by a number of protein assays 
(including both the Lowry and the BCA assays) (Lehre and Danbolt, 1998), and because we 
have been able to produce this protein in non-aggregated form as shown (Fig. 2). The stained 
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gels were scanned using translumination on an Epson Expression 1680 Pro7 scanner and the 
density of the bands was determined both with ImageJ (National Institutes of Health, USA) 
and with ImageMaster TotalLab (Amersham). The two programs gave the same results. 
Because the immunoaffinity isolation method is expensive with regard to antibodies, the 
antigen was always added in excess to ensure saturation of the antibodies. Under these 
conditions, 0.5 ml of gel containing 0.5 mg of immobilized antibodies gave 90-130 g 
EAAC1 protein and 12-20 g remained after the final purification on the wheat germ 
agglutinin-column.  
 
Immunolabeling of blots for quantitative measurements 
Quantitative measurements were made either using 125I-protein A exactly as described 
(Beckstrøm et al., 1999) in combination with anti-C491 (Ab#237; 0.1 - 3 g/ml) or using 
chemoluminescence (Supersignal West Dura™ from Pierce, Rockford, IL, USA) as 
described (Holmseth et al., 2009) in combination with anti-C491 (Ab#371, 0.125 g/ml). The 
immunoreactivities per unit protein in whole tissue homogenates of hippocampus, cerebellum 
and kidney were compared with that of three purified preparations of EAAC1 (Table 1). The 
hippocampal and cerebellar homogenates contained all tissue components because SDS 
dissolves brain tissue completely (a clear solution is obtained). The kidney, however, 
contains water and SDS insoluble components (connective tissue). Therefore the kidney 
homogenates refer only to the components that could be solubilzed. When stated (Table 2) 
hippocampus was first homogenized in water and subjected to high speed centrifugation 
(39,000 x g, 20 min, 4C, Beckman JA20 rotor). The pellet was dissolved in SDS as above 
and referred to as 'Membranes' in Table 2. To determine the regional differences in EAAC1-
levels (Fig. 3) whole tissue homogenates were made from cerebellum, neocortex, olfactory 
bulb, striatum, thalamus/hypothalamus, pons and mesencephalon. The immunoreactivities of 
these homogenates were compared to that of hippocampus using the chemiluminescence 
based method only. The samples were run in triplicates and compared to hippocampus (Fig. 
3A). 
 
Immunocytochemistry 
Perfusion fixation of animals, Vibratome sectioning, and immunoperoxidase staining of 
Vibratome sections, and pre-embedding electron microscopy were done as described before 
(Danbolt et al., 1998). Fluorescence labeling and confocal microscopy were done as 
previously (Holmseth et al., 2005), while post-embedding immunogold 
immunocytochemistry was done according to Furness et al. (2008). The sections were 40 m 
thick. 
 
Estimation of neuronal surface density 
This was done in the stratum radiatum of hippocampus (subfield CA1) about 4 mm from the 
temporal pole using the same material as we have previously used for measuring the glial 
surface density (Lehre and Danbolt, 1998). Tissue components were identified according to 
Peters et al. (1991) and Palay and Chan-Palay (1974). Photographs from serial sections were 
obtained because it is not possible to identify all the cellular processes in a single picture, and 
because this study required identification of all cellular processes in order to obtain a 
measure for the total cell surface. The lengths of all identified dendritic (including spines) 
and astroglial cell membranes, and the area of the analyzed images (104 m2), were measured 
by a computer program from Science Linker AS (Oslo, Norway). Surface areas of dendrites 
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and astroglia were calculated by multiplying the membrane lengths per image area by 4/pi 
(Weibel, 1979). 
 
Electrophysiology 
Slice Preparation: Hippocampal slices were prepared from 12-17 day-old Sprague-Dawley 
rats or mice, in accordance with a protocol approved by the Animal Care and Use Committee 
at Johns Hopkins University.  Animals were anesthetized with halothane and decapitated, the 
hippocampi were dissected free, mounted in agar blocks, cut in 400 m thick transverse 
sections using a vibratome (VT1000S, Leica), in oxygenated ice-cold artificial cerebrospinal 
fluid (ACSF) containing (in mM): NaCl 119, KCl 2.5, CaCl2 2.5, MgCl2 1.3, NaH2PO4 1, 
NaHCO3 26.2 and D Glucose 11.  Slices were allowed to recover on a gauze net submerged 
in ACSF at 37° C for 30 minutes and kept at room temperature thereafter.  For cerebellar 
slices, 250 m thick parasagittal sections were prepared.   
Whole Cell Recording:  Individual brain slices were placed in a chamber mounted on an 
upright microscope (Zeiss, Axioskop FS2) and continuously superfused with oxygenated 
ACSF. Individual cells (astrocytes, CA1 pyramidal neurons, or Purkinje neurons) were 
visualized through a 40x water immersion objective (Olympus LUMPlanFL, NA = 0.8) using 
infrared-Nomarski optics and a CCD camera (Sony XC-73).  Recording electrodes were 
pulled from glass capillary tubing and had a combined resistance of 1.5-3.0 M when filled 
with the internal solution.  For astrocytes, the internal solution contained (in mM): KCH3O3S 
(KMeS) 120, EGTA 10, HEPES 20, MgCl2 1, Na2ATP 2, NaGTP 0.2; the pH was 7.3.  To 
record transporter associated anion currents from CA1 pyramidal neurons and Purkinje 
neurons, the internal solution contained (in mM): CsNO3 100, TEA-Cl 20, EGTA 10, HEPES 
20, MgCl2 1, QX-314 1, Na2ATP 2, NaGTP 0.2; the pH was 7.3. With these solutions the 
series resistance during recordings was <10 M, and was left uncompensated.  Unless stated 
otherwise, holding potentials have not been corrected for the junction potential.  Whole-cell 
currents were amplified using an Axon Multiclamp 700A (Axon Instruments), filtered at 2-5 
kHz and sampled at 10-20 kHz.   
Solution Application: Caged compounds were dissolved in HEPES buffered saline (HEPES 
ACSF) containing (in mM): NaCl 137, KCl 2.5, CaCl2 2.5, MgCl2 1.3, HEPES 20; the pH 
was 7.3.  Solutions containing caged compounds were applied to the slice using a wide bore 
(tip diameter 50-100 m) pipette connected to a manifold fed by four 10 ml reservoirs.  
Solutions were switched by alternately opening and closing valves attached to each reservoir. 
 Antagonists were used to block voltage-gated Na+ channels (tetrodotoxin; TTX, 1 M), 
AMPA/kainate receptors (2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-
sulfonamide disodium salt; NBQX, 10 M), NMDA receptors ((RS)-3-(2-carboxypiperazin-
4-yl)-propyl-1-phosphonic acid; R,S-CPP, 10 M; and (5R,10S)-(+)-5-methyl-10,11-
dihydro-5H-dibenzo[a,d]cyclo-hepten-5,10-imine hydrogen maleate; MK-801, 50 M), and 
GABAA receptors (6-imino-3-(4-methoxyphenyl)-1(6H)-pyridazinebutanoic acid 
dihydrobromide; SR-95531, 5 M).  In some experiments, group I mGluRs were blocked 
with LY367385 (100 M).  Glutamate transporters were inhibited using DL-threo--
benzyloxyaspartic acid (TBOA, 100-200 M).   
Photolysis:  UV light (333.6-363.8 nm) was delivered to the sample by coupling the output of 
an argon ion laser (Stabilite 2017-AR, Spectra-Physics) to a multi-mode quartz fiber optic 
cable (Oz Optics Ltd.).  The output of the fiber optic was collimated using a quartz lens, 
projected through the fluorescence port of a Zeiss Axioskop FS2 microscope, and focused to 
a ~50 m spot using a 40x water immersion objective (Olympus LUMPlanFl).  MNI-D-
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aspartate was applied to cells locally through a wide bore pipette, and photolysis achieved by 
brief (~1 ms) exposure to UV light, as described (Huang et al., 2005). 
 
Preparation of hippocampal slices from adult rat brains 
Hippocampal slices were prepared and incubated with D-aspartate essentially as described 
previously (Furness et al., 2008). Briefly, fresh rat hippocampal slices were incubated in 
Krebs' phosphate solution (140 mM NaCl, 5 mM KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 10 
mM glucose and 15 mM sodium phosphate buffer, pH 7.4) with 1 - 50 M D-aspartate. 
Negative controls were treated as above, but incubated either in the absence of D-aspartate or 
with the addition of 1 mM L-glutamate. Following incubation, slices were fixed using 1 % 
formaldehyde and 2.5 % glutaraldehyde in 0.1 M sodium phosphate buffer, embedded by 
freeze substitution (Dehnes et al., 1998) and processed for immunogold transmission electron 
microscopy.  
 
Reconstitution of glutamate transporters into proteoliposomes 
This was done as previously described (Danbolt et al., 1990). Briefly, crude rat brain was 
homogenized in 10-20 volumes of ice-cold water with 5 mM EDTA and 1 mM PMSF. After 
centrifugation (39000 x g, 20 min, 4°C), the pellet was solubilized and centrifuged as above. 
The supernatant was mixed with a phospholipid cholate salt mixture, incubated on ice and gel 
filtered (Trotti et al., 1995) to remove detergent and sodium ions equilibrated with the desired 
internal medium.  
 
RNA isolation, cDNA synthesis and TaqMan Assays   
This was done as described previously (Lehre et al., 2011) Pieces of tissue (5-15 mg) were 
collected and immediately protected in RNAlater  (Ambion/Applied Biosystems, TX, USA), 
before homogenization and RNA extraction using RNeasy® (Qiagen, Hilden, Germany). The 
RNA concentration was quantified by using NanoDrop UV spectrometry (NanoDrop 
Technologies, Wilmington, USA). Two g RNA were converted into cDNA by using High 
Capacity cDNA Archive Kit (Applied Biosystems; Carlsbad, CA, USA). EAAC1 mRNA 
expression was measured using TaqMan probes (Mm00436590_m1) on a 7900HT Fast Real-
Time PCR system (Applied Biosystems; Carlsba, CA, USA).  The probe which was used to 
detect GAPDH (as control) was Mm03302249_g1. 
 
 
RESULTS 
The concentration of EAAC1 protein in young adult rat hippocampus and kidney 
Antibodies to EAAC1 were produced (Fig. 1) and used to immunoisolate EAAC1 protein 
from rat kidney. Three highly purified preparations of EAAC1 protein were obtained (Fig. 2, 
lanes 5-8; Table 1). To circumvent the problem of partial aggregation (see Methods), the 
concentrations of the monomer in these preparations were determined densitometrically on 
silver stained gels by comparing with known amounts of pure GLT1 protein (Fig. 2, lanes 1-
4). Then, immunoreactivity of the EAAC1 monomer in the three purified preparations (Table 
1) was compared with that of the EAAC1 monomers in tissue extracts (Fig. 3a; Table 2) and 
found to correspond to 0.10 ± 0.011 mg, 0.16 ± 0.004 mg  and 0.13 ±  0.013 mg EAAC1 
monomer, respectively (mean ± SEM), per gram total protein. From this, we concluded that 
the concentration of EAAC1-protein in young adult rat hippocampus tissue is about 0.013 ± 
0.02 mg per gram (tissue wet weight). For kidney whole-tissue extracts the corresponding  
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Detergent 
 
Rat age 
 
Antibody 
ID 
 
Amount of pure 
EAAC1 protein 
 
WGA 
 
DEAE 
 
Sample 
ID 
 
Cholate 
 
220-240 
gm 
 
Ab#237 
 
88 g 
 
No 
 
Yes 
 
1374 
 
SDS 
 
9 w 
 
Ab#555 
 
12 g 
 
Yes 
 
No 
 
1357 
 
SDS 
 
9 w 
 
Ab#555 
 
20 g 
 
Yes 
 
No 
 
1358 
Table 1. Isolation of EAAC1 protein from rat kidney : Rat kidneys were solubilized in cholate or SDS and 
EAAC1 isolated using immobilized anti-C491 antibodies (either Ab#237 or Ab#555). The bound EAAC1 
protein was eluted at low pH, neutralized and further purified by chromatography on either a wheat germ 
agglutinin lectin (WGA) column or a diethylaminoethyl (DEAE) column as indicated. The age is given in 
weight (gm) or in weeks (w). 
 
numbers were 0.014 ± 0.001 and 0.02 ± 0.002 mg per gram tissue (from two purified 
preparations, Table 1: #1357 and #1358). In the cerebellum, the amount was found to be 
lower, around 0.003 ± 0.0005 mg per gram cerebellar tissue (based on #1374). When the 
molecular mass of EAAC1 (58 kDa) is taken into account, it follows that the EAAC1 
concentration in hippocampal neuropil is 1.3 x 1017 molecules per liter tissue or 0.22 M, 
corresponding to about 130 EAAC1 molecules per cubic micrometer (Table 3). As there is 
approximately one nerve terminal per cubic micrometer in the rat stratum radium (Woolley 
and McEwen, 1992), 
it follows that there 
are on average about 
130 EAAC1 
transporters at each 
excitatory synapse in 
this region.  
 
 
Figure 1. The specificity 
of the EAAC1 antibodies 
as demonstrated by 
immunoblotting of 
electrophoretically 
separated proteins from 
(A) rat hippocampus, (B) 
rat kidney, and (C) wild-
type and (D) EAAC1 
knockout mice 
hippocampi. The blot 
strips were incubated 
with: Lane 1, anti-C491 
(Ab#371); lane 2, anti-
C491 (Ab#237); lane 3, anti-C479 (Ab#359); lane 4, sheep anti-C510 (Ab#565); lane 5, anti-C510 (Ab#126); 
lane 6, anti-B12 (Ab#152), (positive control), and lane 7, no primary antibody (negative control). Each strip 
contained 16 μg of protein. The absence of labeling in EAAC1-knock out mice (Panel D, lane 1-5) attests the 
specificity of the antibodies. All antibodies were used at a concentration of 1 μg/ml except for anti-B12 which 
was used at 0.2 μg/ml.  
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Figure 2. Determination of the concentration of monomeric EAAC1-
protein in the purified preparations of EAAC1 protein. Highly purified 
GLT1 protein (50, 100, 200 and 350 ng in lanes 1-4, respectively) and 
a purified preparation of EAAC1 (5, 10, 20 and 35 μl in lanes 5-8, 
respectively) were subjected to SDS-PAGE and silver stained 
(Danbolt et al., 1990). The optical densities of the GLT1 bands were 
used as a standard to determine the protein concentration of the 
EAAC1 sample. 
 
 
Glutamate uptake in GLT1-deficient mice 
The above data suggest that EAAC1 is expressed at levels 
that are about 100 times lower than those of GLT1 (Table 
3). This is in agreement with the low uptake activities 
observed in synaptosome preparations from GLT1 
deficient mice (Tanaka et al., 1997). However, we have 
recently shown that synaptosome preparations mostly 
detect GLT1 catalyzed glutamate uptake into terminals 
(Furness et al., 2008). The possibility therefore existed that EAAC1 expressed in other 
compartments could have been underestimated. To obtain an estimate for the total uptake 
activity of all transporters in the tissue independently of whether they are present in cellular 
compartments that do not reseal after homogenization, we solubilized the tissue in cholate 
and reconstituted the transporters in artificial cell membranes (liposomes) containing internal 
potassium as we have done previously (Danbolt et al., 1990). These liposome preparations 
did not give any indications that EAAC1 is a major player because the glutamate uptake 
activity in liposomes prepared from GLT1 knockout tissue (forebrain) was very low (about 2 
% of wild-type) compared to that of liposomes prepared from wild-type tissue (Fig. 4A). 
GABA uptake activity was used as a positive control, and was found to be similar in 
liposomes made from wild type and GLT1 knockout mice (Fig. 4B). The ionophore nigericin 
was used as a negative control because it compromises the transmembrane ion gradients. It 
abolished all uptake activity (of both glutamate and GABA). Further, immunoblots showed 
that GLT1-deficient mice have normal levels of EAAC1 (Fig. 4C). Although EAAT4 was 
readily detected in the cerebellum, detection of the tiny amounts of EAAT4 present in the 
forebrain requires other methods (see: Dehnes et al., 1998). 
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Animal 
 
Age 
 
Region 
 
Type 
 
Detection 
system 
 
mg EAAC1 per gram 
total protein 
 
1 
 
220 gm 
 
Hippoc 
 
Whole 
 
125I-Prot A 
 
0.20 
 
2 
 
220 gm 
 
Hippoc 
 
Whole 
 
125I-Prot A 
 
0.17 
 
3 
 
220 gm 
 
Hippoc 
 
Whole 
 
125I-Prot A 
 
0.13 
 
1 
 
220 gm 
 
Cerebel 
 
Whole 
 
125I-Prot A 
 
0.038 
 
2 
 
220 gm 
 
Cerebel 
 
Whole 
 
125I-Prot A 
 
0.031 
 
3 
 
220 gm 
 
Cerebel 
 
Whole 
 
125I-Prot A 
 
0.021 
 
4 
 
220 gm 
 
Hippoc 
 
Membr 
 
125I-Prot A 
 
0.27* 
 
5 
 
220 gm 
 
Hippoc 
 
Membr 
 
125I-Prot A 
 
0.25* 
 
6 
 
220 gm 
 
Hippoc 
 
Membr 
 
125I-Prot A 
 
0.24* 
 
7 
 
18 w 
 
Hippoc 
 
Membr 
 
125I-Prot A 
 
0.16* 
 
8 
 
8 w, f 
 
Hippoc 
 
Membr 
 
125I-Prot A 
 
0.19* 
 
9 
 
8 w, f 
 
Hippoc 
 
Membr 
 
125I-Prot A 
 
0.17* 
 
10 
 
14 w 
 
Hippoc 
 
Whole 
 
Chemolum 
 
0.08 
 
11 
 
14 w 
 
Hippoc 
 
Whole 
 
Chemolum 
 
0.11 
 
12 
 
14 w 
 
Hippoc 
 
Whole 
 
Chemolum 
 
0.08 
 
13 
 
9 w 
 
Hippoc 
 
Whole 
 
Chemolum 
 
0.11 
 
14 
 
9 w 
 
Hippoc 
 
Whole 
 
Chemolum 
 
0.13 
 
15 
 
9 w 
 
Hippoc 
 
Whole 
 
Chemolum 
 
0.16 
 
16 
 
9 w 
 
Hippoc 
 
Whole 
 
Chemolum 
 
0.17 
 
17 
 
9 w 
 
Hippoc 
 
Whole 
 
Chemolum 
 
0.16 
 
18 
 
9 w 
 
Hippoc 
 
Whole 
 
Chemolum 
 
0.15 
 
19 
 
9 w 
 
Hippoc 
 
Whole 
 
Chemolum 
 
0.17 
Table 2. Quantification of EAAC1 protein in rat brain tissue: The amounts of EAAC1 protein in tissue from 
the hippocampus (Hippoc) and cerebellum (Cerebel) were measured by immunoblotting using purified 
preparations of EAAC1 protein (Table 1) as standards. The measurements of the levels in animals 1-9 are based 
on anti-C491 (Ab#237) and the first EAAC1 preparation (Table 1, Sample #1374) while the other measurements 
(animal 10-19) are based on anti-C491 (Ab#555) and the two other EAAC1 preparations. Bound antibodies were 
detected either with iodinated protein A or with chemoluminiscence (Chemolum) as indicated. Note that 
cerebellum contains less EAAC1 than hippocampus in agreement with figure 3. Also note that some tissue 
samples were homogenized in water to remove water soluble proteins before solubilization in SDS. These are 
indicated (Membr) in contrast to the rest which were solubilized directly (Whole). Water soluble proteins 
represent about 50 % of the total brain proteins, but do not contain any detectable amounts of EAAC1 (data not 
shown) the water insoluble fraction (Membr) are therefore 2-fold enriched with respect to EAAC1. The age is 
given in weight (gm) or in weeks (w). All animals were males except those indicated (f). 
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Figure 3. Quantification of EAAC1 protein and mRNA. 
Panel A: Immunoblot of hippocampus and purified EAAC1 
(two different preparations were used as standards, only one 
of the preparations is shown here: 2.7, 1.35, 0.9, 0.45, 0.3, 
and 0.15 ng EAAC1 in lanes 7-12, respectively). The 
concentration of EAAC1 in hippocampus was measured by 
comparing the immunoreactivities of the tissue proteins 
(13.5, 9, 4.5, 3, 1.5, and 1 μg protein in lanes 1-6, 
respectively) with that of known amounts of the pure 
EAAC1 protein. Panel B: Quantitative distribution of 
EAAC1 in different regions of rat brain. Immunoblots with 
2.5 g protein/lane were reacted with 0.3 g/ml anti-C491 
(Ab#555). Bound antibodies were detected by 
chemiluminescence. The bands were located with exposure 
to X-ray film, and the different staining intensities on the 
film were analyzed with ImageJ (see Materials and 
methods). The results represent mean ± SEM of three sets of 
immunoblots (from three different Wistar rats aged 9 - 12 
weeks). The values obtained from the region with highest 
immunoreactivity (hippocampus) were arbitrarily defined as 
100 %, and the values from the other regions were 
expressed as percentage of this highest value. Regions: B, 
olfactory bulb; H, hippocampus; X, neocortex; S, corpus 
striatum; T, thalamus/hypothalamus; M, mesencephalon; P, 
pons; C: cerebellum. Panel C: The EAAC1 mRNA levels in 
mouse tissues (12 weeks old) including olfactory bulb(B), 
hippocampus (H), cortex (X),  hypothalamus (Ht), thalamus 
(T), brain stem (Bs), cerebellum (C), kidney (K), liver (L), 
duodenum (D), ileum (I) and colon (C) were measured 
using TaqMan probe Mm00436590_m1 and expressed 
relative to the levels in hippocampus. Note that the highest 
levels of EAAC1 mRNA were in the intestine, kidney and 
hippocampus. 
 
 
Regional distribution of EAAC1 protein and 
mRNA in the young adult rat 
After having determined the concentration of 
EAAC1 protein in hippocampus, other brain 
regions were compared to hippocampus by 
immunoblotting (Fig. 3B). The concentrations in the striatum, neocortex, olfactory bulb, and 
thalamus/hypothalamus (in decreasing order) were approximately half of that in the 
hippocampus. The levels in the cerebellum, mesencephalon, and pons/medulla oblongata (in 
decreasing order) were at about one third to one quarter of the hippocampal level in 
agreement with the quantification (see above). These data are in reasonable agreement with 
the mRNA levels (Fig. 3C) and with the regional labeling intensity seen on tissue sections 
(Fig. 6) when the latter were processed in the presence of Triton X-100 to maximize 
penetration of the reagents (Lehre et al., 1995).  
 It was noted that the electrophoretic mobility of EAAC1 from striatum was slightly 
lower than that of EAAC1 from the other brain regions tested (data not shown) resembling 
the situation with cerebellar GLAST (EAAT1) which runs more slowly than that from the 
rest of the brain (Lehre et al., 1995). 
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Figure 4. There is very little glutamate uptake activity remaining 
when GLT1 is knocked out. Panel A: L-[3H]glutamate uptake in 
proteoliposomes prepared from forebrains from wild-type and 
GLT1 knockout mice. Note that the uptake in proteoliposomes 
prepared from GLT1 knockout tissue is negligible compared to 
those prepared from wild-type tissue. The uptake depends on the 
electrochemical gradients as illustrated by the fact that addition 
nigericin abolish all uptake activity. Panel B: GABA uptake 
activity in the same preparations of proteoliposomes. Note that 
the liposomes that were unable to take up L-[3H]glutamate, take 
up [3H]GABA as well as those prepared from wild-type tissue 
implying that the reconstitution process has been successful. 
Panel C: Immunoblots from forebrains of wild-type (WT) and 
GLT1 knockout (KO) mice show that GLT1 is absent while 
EAAC1 and GLAST is still present at normal levels. The 
amounts of protein in each lane were 1, 3 or 10 μg as indicated. 
The blots were developed with antibody anti-C479 (Ab#371; 1 
μg/ml) for EAAC1, anti-A522 (Ab#314; 0.2 μg/ml) for GLAST 
and anti-B12 (Ab#355; 0.1 μg/ml) for GLT1. 
 
  
 
 
Figure 5. Changes in glutamate transporter expression during 
brain development. GLAST, GLT1, EAAC1 and EAAT4 protein 
expression were analyzed in rat forebrain and cerebellum tissue 
from E16 to adult age (two months). Note that the EAAC1 
concentration in the forebrain is at its highest at P14. Three 
animals were tested at each age, but the figure only shows one of them. Abbreviations: E, embryonal day; P, 
postnatal day; A, adult. Each lane contained 20 μg protein and the blots were developed with antibody, anti-
A522 (Ab#314; 0.2 μg/ml) for GLAST and anti-B12 (Ab#291; 0.2 μg/ml) for GLT1, anti-C491 (Ab#237; 1 
μg/ml) for EAAC1 and anti-D537 (Ab#181; 1 μg/ml) for EAAT4. 
 
Changes in EAAC1 concentrations during development  
Rat brain tissue from E16 to adult was immunoblotted with antibodies to four different 
glutamate transporter subtypes. In contrast to the dramatic upregulation of GLAST and GLT1 
in the hippocampus with age (Furuta et al., 1997; Ullensvang et al., 1997), only modest 
changes in the expression of EAAC1 were observed with age (Fig. 5). EAAC1 levels 
increased after birth and peaked at P14, before decreasing by a factor of three over the next 
six weeks. These results suggest that there is a transient increase in demand for EAAC1 
activity during early postnatal life. 
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Antibody specificity on 
sections of aldehyde 
fixed tissue 
Because intact fixed 
tissue might contain 
epitopes that are not 
present on immunoblots 
and vice versa, the 
antibodies were also 
tested on sections of 
wild-type and EAAC1-
knockout mice (Fig. 6). 
As shown previously 
(Holmseth et al., 2005, 
2011), the anti-C491 
antibodies recognize 
both rat and mice, while 
the anti-C479 antibodies 
produce only weak 
labeling of mouse 
sections and 
immunoblots (Fig. 1A3 
vs. 1C3; Fig. 6). Most 
brain regions in EAAC1 
deficient mice displayed 
very little labeling when 
compared to the same 
regions in the wild-type 
mice. However, the anti-  
 
Figure 6. Diaminobenzidine-peroxidase labeling of brain sections from rat and mice (wild-type and EAAC1 
deficient) with three different EAAC1 antibodies. High magnifications of hippocampus are shown below the 
overview pictures. Note that anti-C510 gave the best contrast between the wild-type and the knockout tissue. 
Anti-C479 produced only weak labeling in the mouse sections (like for immunoblots, as shown in figure 1C, 
lane 3), while anti-C491 produced some labeling in the knockout. Antibodies: anti-C479 (Ab#359; 10 μg/ml), 
anti-C491 (Ab#371; 0.3 μg/ml), and anti-C510 (Ab#565; 10 μg/ml). Triton X-100 (0.5 %) was included in the 
solutions. Rat and mouse tissue perfusion fixed with 4 % formaldehyde and 0.1% glutaraldehyde in 0.1 M 
sodium phosphate buffer. Rats were 14 weeks old, and mice 4 weeks old. Scale bar, 2 mm. 
 
 
C491 antibodies (Ab#371) produced some labeling in EAAC1 deficient tissue (Fig. 6), 
although they appeared specific on immunoblots (Fig. 1 present study; Holmseth et al., 
2011). Labeling in the knockout mice was observed in the hippocampus CA1-3 (CA2 in 
particular) and in the striatum as well as in some other places (e.g. piriform cortex). The 
identity of the cross-reacting molecule(s) was not determined, but it appears to have a cellular 
expression profile similar to EAAC1. The labeling in the EAAC1-deficient mice was only 
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seen in neurons (somato-dendritic compartment) and was thereby expressed in the same cells 
as those expressing EAAC1 (data not shown).  
  Note that the regional labeling patterns in mouse and rat obtained with the three 
antibodies are quite similar. As shown (Fig. 6) some differences in the hippocampus were 
noted, but these should not be over interpreted as it is difficult to get all parameters identical 
(animal age, fixation time, post fixation time, storage, time from sectioning to labeling, all of 
the assay conditions such as presence or absence of Triton X-100, etc.) and EAAC1-deficient 
rats were not available. Consequently, we cannot tell if these differences between mouse or 
rat are real. We did not pursue this question because the answer will have no impact on the 
conclusions of this study. 
 
Figure 7. High magnification of hippocampus 
CA3 from EAAC1 wild-type mouse (4 weeks 
old) labeled with anti-C510 (Ab#565; 10 
μg/ml). Note that cytoplasm in neuronal somata 
of pyramidal cells and dendrites are labeled 
(arrows). Pyramidal cell nuclei (p) are unlabeled 
(only three are indicated). The tissue was 
perfusion fixed with 4 % formaldehyde and 
0.1% glutaraldehyde in 0.1 M sodium phosphate 
buffer and processed  in the absence of Triton 
X-100. Scale bar=20 m. 
 
Cellular and subcellular localization 
of EAAC1 
Vibratome sections of perfusion fixed 
rat brain were labeled with the various 
antibodies to EAAC1 in the absence of 
Triton X-100 using peroxidase as 
reporter. Light microscopy showed that 
labeling intensities varied between the various hippocampal subfields, with highest labeling 
observed in the dentate gyrus and the CA1 subfield. In these areas, we observed labeling of 
neuronal cell bodies and dendrites in both rats and wild-type mice with all the available anti-
EAAC1 antibodies (Figs. 7, 8D). EAAC1 was found in all cells identified as neurons, 
including parvalbumin positive hippocampal interneurons (Fig. 8). In contrast, no labeling of 
endothelium was observed. Furthermore, the choroid plexus and the lining of the ventricles 
also were unlabeled, indicating that  
EAAC1 was not expressed by ependymal cells or tanycytes.  
We also did not detect EAAC1 in astrocytes in the adult or juvenile neocortex and 
hippocampus. Double labeling of sections with EAAC1 in combination with GLT1 (Fig. 9A), 
glial fibrillary acidic protein (GFAP, Fig. 9B), glutamine synthetase (GS, Fig. 9C, D, E, F, G) 
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Figure 8.  Hippocampal GABAergic interneurons expressing parvalbumin also express EAAC1. Panels A-C: 
(A, green) anti-parvalbumin (1:500), (B, red) anti-EAAC1 (anti-C510; Ab#565, 10 g /ml) and (C) a merged 
picture of the two. Panel D:  anti-EAAC1 (anti-C510; Ab#565, 10 g /ml) developed with the diaminobenzidine-
peroxidase labeling system. Note that both EAAC1 and parvalbumin are expressed in cell bodies in stratum 
pyramidale (arrow head) and stratum radiatum (arrows). The tissue in A-C is from mouse, 3 weeks old perfusion 
fixed with 4 % formaldehyde in 0.1 M NaPi. D is form a 3 weeks old mouse perfusion fixed with 4 % 
formaldehyde and 0.05 % glutaraldehyde in 0.1 M NaPi. Scale bars, 20 μm 
 
or GLAST (Fig. 9H) did not reveal any co-localization between EAAC1 and astrocytic 
markers. Two different GLT1 antibodies were used as a positive control for co-localization  
(Fig. 9I). In the corpus callosum  there also was no co-localization of EAAC1 with markers 
for mature oligodendrocytes (myelin basic protein, MBP; CNPase), and the EAAC1-
immunoreactive cells were scattered rather than organized in string-like arrays typical of 
oligodendrocytes (Fig. 10). EAAC1 immunoreactivity also did not co-localize with NG2, 
indicating that this transporter is not expressed by oligodendrocyte precursor cells (NG2 
cells) or pericytes. This is in agreement with a previous report (Berger and Hediger, 1998) 
where it was suggested that EAAC1 immunoreactive cells in the corpus callosum represent  
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 Figure 9. Double labeling with three different EAAC1 antibodies (red) and different astrocyte markers (green). 
In A-C anti-C491 (Ab#371, 0.5 g /ml) is used together with the following markers: GLT1 (A, 1:500), glial 
fibrillary acidic protein (GFAP) (B, 1:500), and glutamine synthetase (GS) (C, 1:500) in rat neocortex. In D-E 
anti-C479 (Ab#359, 3 g /ml) is used together with glutamine synthetase in rat neocortex (D) and in rat 
hippocampus CA1 (E). In F-H anti-C510 (Ab#565, 30 g /ml) is used together with glutamine synthetase (F-G) 
or anti-GLAST (Banner et al., 2002)  1:500 (H) as indicated. F and H are from mouse hippocampus CA1, while 
G is from mouse neocortex. Double labeling with mouse anti-GLT1 (9C4; Ab#531, 1:30) and rabbit anti-GLT1 
(Ab#360, 0.5 g /ml) is a positive control for co-localization (I). Note that there is no significant co-localization 
between EAAC1 and the various astroglial markers. Rat and mouse tissue perfusion fixed with 4 % 
formaldehyde in 0.1 M Sodium phosphate buffer. Rats were 9 weeks old, and mice 3 weeks old. Abbreviations: 
M-hip, mouse hippocampus; M-neo, mouse neocortex; R-hip, rat hippocampus; R-neo, rat neocortex. Scale bars, 
10 μm. 
 
interneurons. In contrast to the strong immunoreactivity observed in the soma and dendrites 
of neurons, there was no detectable co-localization between EAAC1 and markers for nerve 
terminals in the neocortex, hippocampus, or cerebellar nuclei. As shown (Fig. 11), EAAC1 
antibodies did not label the structures that were labeled with antibodies to synaptophysin, 
GAD and VGLUT1. It is clear from these sections that EAAC1 labeling was largely 
intracellular in the brain. This is in contrast to the kidney where EAAC1 is concentrated at 
the cell surface, particularly in the brush border of proximal tubules (Fig. 12). 
 The EAAC immunoreactivity observed electron microscopically (Fig. 13) was weak 
in agreement with figure 7. The very strong labeling that we have previously observed with 
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a  
Figure 10. Double labeling with various EAAC1 antibodies (red) and markers for oligodendrocytes (green) in 
corpus callosum from adult mouse. In A and C anti-C479 (Ab#359, 3 g/ml) is used together with the anti-
myelin basic protein (MBP) (A, 1:500) and anti-glutamine synthetase (GS, C, 1:500). In B and D anti-C491 
(Ab#371, 0.5 g /ml) is used together with anti-NG2 (B, 1:500) and anti-CNPase (D, 1:500). Note that there is 
no detectable co-localization with any of the glial markers. Scale bar: 10 μm.  
 
antibodies to GLT1 and GLAST (e.g. Danbolt et al., 1992; Levy et al., 1993; Chaudhry et al., 
1995; Lehre et al., 1995) and to EAAT4 in the cerebellum (Dehnes et al., 1998) was not only 
due to good antibodies and good tissue processing, but also due to the very high expression 
levels of these proteins (Lehre and Danbolt, 1998). With GLT1 antibodies and gold-labeled 
secondary antibodies, we observed on average, when using the best antibodies, around 10 
gold particles per micrometer membrane length, and background labeling was not a problem 
(Chaudhry et al., 1995; Furness et al., 2008). Considering that EAAC1 is expressed at levels 
two order of magnitude lower, it is not surprising that the immunogold labeling was similar 
to the background level observed in the EAAC1-knockout tissue. In fact, if the labeling is 
specific for EAAC1, then this is exactly what should be expected. 
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 Figure 11. Double labeling with EAAC1 (red) and various markers for nerve terminals (green). A-D 
shows EAAC1 labeled with anti-C491 (Ab#371, 1 g /ml) together with anti-synaptophysin (1:1000) (A), anti-
GAD (1:500) (B and D), and anti-VGLUT1 (1:200). Note that there is no detectable co-localization with any of 
the markers for terminals. Pictures A-C are from hippocampus CA1, while D is from the cerebellar nuclei. Rat 
tissue (9 weeks) was perfusion fixed with 4 % formaldehyde in 0.1 M sodium phosphate buffer. Scale bars, 20 
μm.axons, or glial cell processes. Although there was some labeling of the outer membranes of mitochondria, 
this is likely to be an artifact, because mitochondria have been shown not to contain EAAC1 (Holmseth et al., 
2006). Together, these studies show that EAAC1 is predominantly intracellular, but is expressed at such low 
levels that it is close to the detection limit using immunolabeling approaches suitable for electron microscopy. 
Immunofluorescence and confocal microscopy is more sensitive (but has lower resolution). 
 
The EAAC1 labeling that we did detect, was intracellularly in perikaria and dendrites, where 
it was associated with structures resembling vesicular clusters and patches of plasma 
membranes (Fig. 13). No labeling was observed in structures clearly identified as terminals,  
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Figure 12. Double labeling with EAAC1 (red) and a marker for renal proximal tubules (Lotus tetragonolobus 
lectin; green). A shows Lotus tetragonolobus lectin (1:300), B shows EAAC1 labeled with anti-C510 (Ab#565, 
3 g/ml), C shows cell nuclei (DAPI staining) and D is a merged picture of the three. Note that EAAC1 is 
concentrated in the brush border of proximal tubules. Mouse tissue (12 weeks) was perfusion fixed with 4 % 
formaldehyde and 0.1 % glutaraldehyde in 0.1 M sodium phosphate buffer. Scale bar, 10 μm. 
 
axons, or glial cell processes. Although there was some labeling of the outer membranes of 
mitochondria, this is likely to be an artifact, because mitochondria have been shown not to 
contain EAAC1 (Holmseth et al., 2006). Together, these studies show that EAAC1 is 
predominantly intracellular, but is expressed at such low levels that it is close to the detection 
limit using immunolabeling approaches suitable for electron microscopy. 
Immunofluorescence and confocal microscopy is more sensitive (but has lower resolution). 
 
The number of EAAC1 molecules per square micrometer plasma membrane 
As shown previously (Furness et al., 2008), the most important factor contributing to surface 
densities is whether or not a protein is expressed in axons and terminals because these 
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structures account for about three quarters of the total plasma membranes in stratum radiatum 
of hippocampus CA1. The dendritic surface area in this area is 1.5 m2/m3, similar to the  
surface area of spines in the molecular layer of the cerebellum (1.1 m2/m3 ) (Dehnes et al., 
1998). The astroglial surface area, which was included as a control, is 1.4 m2/m3, and thus 
identical to our previous analysis using a different stereological method (Lehre and Danbolt, 
1998). Given the measured EAAC1concentrations (Tables 2 and 3), the mean EAAC1 
density is about 90 molecules per square micrometer of dendritic membrane, provided all 
EAAC1 is inserted into the membrane. However, as most of the EAAC1 is located 
intracellularly, this is a significant overestimation. The above calculations therefore assume 
that EAAC1 is evenly distributed. As can be seen in Fig. 6 this is an approximation.  
 
 
 
Figure 13. Electron micrographs from dentate gyrus molecular layer of wild-type mouse showing postsynaptic 
neuronal EAAC1 labeling. Labeling is found in dendritic compartments (d), including spines (s). Arrowheads 
point at labeling at the cell membrane in spines. Note that the labeling appears more patchy than the astrocytic 
GLT and GLAST membrane labeling produced with the same method in our previous studies (Lehre et al., 
1995). Mitochondria (m) are indicated. Boutons (b) appear unlabelled. Antibody: anti-C510 (Ab#565; 10 
μg/ml). Mouse tissue (4 weeks) was perfusion fixed with 4 % formaldehyde and 0.05 % glutaraldehyde in 0.1 M 
sodium phosphate buffer. Scale bars, 300 nm. 
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Table 3. Tissue concentrations of glutamate transporters in the hippocampus (stratum radiatum, CA1) of 
young adult Wistar rats                                                                                                                        
 
 mg per M Molecules m2/m3 Location Percent Molecules 
 g tissue  per m3   the surface  per m2 
                                                                                                                                                                    
 
GLAST1 0.32  5.3   3200 1.4  Astroglia ~100 % 2300 
 
GLT11 1.3  21 12000 1.4  Astroglia2 ~100 % 75002 
                                                                                              Terminals   ~10 %   750 
 
EAAC1 0.013 0.22     130 1.5 Dendrites 0-100 %  0-903 
                                                                                                                                                                    
 
The above data only give an indication of the average transporter densities because expression levels are subject 
to regulation. Further, EAAC1 is to a large extent present intracellularly in the brain (e.g. Figs. 7 and 8) while 
most of GLT1 and GLAST are at the surface. The calculations further assume that brain tissue contains about 
97.8 g protein per Kg (Lowry et al., 1954) and has a density of 1.05 g/cm3 (Lowry, 1953) (i.e. 1 m3 contains 
about 10-13g protein), and that the molecular masses of the polypeptide parts of rat EAAT1 (Storck et al., 1992), 
EAAT2 (Pines et al., 1992) and EAAC1 (Kanai and Hediger, 1992) are 60, 62 and 58 kDa, respectively. The 
total plasma membrane density was about 14 m2/m3. Axons represents about 70 % of this while astroglia, 
butons, dendrites including spines represent about 10 % each (Furness et al., 2008). 
1 Data from Lehre and Danbolt, 1998. 
2 It is now clear that about 10% of the EAAT2 is also present in synaptic terminals (Furness et al, 2008) 
implying that the number 8500 given in Lehre and Danbolt, 1998 is slightly too high. 
3 A range is given because it is unclear how much is in the membrane. 
 
Lack of detectable glutamate transporter currents in hippocampal CA1 pyramidal 
neurons 
To determine whether the surface density of EAAC1 in hippocampal neurons is sufficient to 
produce detectible transporter currents, we made whole cell voltage clamp recordings from 
CA1 pyramidal neurons using solutions appropriate to maximize transporter current 
amplitude. Although photolysis of caged D-aspartate (MNI-D-aspartate), a substrate of 
glutamate transporters, reliably elicited large inward currents in hippocampal astrocytes (–
415 ± 67 pA, n = 6) (Fig. 14A) and cerebellar Purkinje neurons (–634 ± 63 pA, n = 8) (Fig 
14B) in rat CNS tissue, which were inhibited by the glutamate transporter antagonist DL-
threo--benzyloxyaspartate (TBOA; 200 μM), only small responses were observed in 
hippocampal pyramidal neurons (–9 ± 2 pA, n = 7) (Fig 14C1). These small currents were not 
sensitive to TBOA, and responses with similar kinetics were observed in both wild-type (–6 
± 1 pA, n = 3) and EAAC1-deficient mice (–5 ± 1 pA, n = 5; P > 1), indicating that they did 
not arise from cycling of EAAC1. These findings are in agreement with earlier studies which 
found that evoked release of glutamate from Schaffer collateral fibers in rat did not elicit 
transporter currents in CA1 pyramidal neurons (Bergles and Jahr, 1998), providing further 
support for the conclusion that few functional EAAC1 transporters are present at the cell 
surface of these neurons.   
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Figure 14. Glutamate transporter currents are 
visible in hippocampal astrocytes and 
cerebellar Purkinje neurons, but not 
hippocampal CA1 pyramidal neurons. (A) A 
transient inward current was elicited in an 
astrocyte by a 1 ms flash of UV laser light. 
The inward current was observed only in the 
presence of MNI-D-aspartate (MNI-D-Asp, 
125 μM), and was inhibited by TBOA (200 
μM). The trace above shows the duration of 
UV exposure. Recordings were made from 
astrocytes located in stratum radiatum of area 
CA1, in the presence of TTX (1 μM), R,S-
CPP (10 μM), MK-801 (50 μM), NBQX (10 
μM) and SR95531 (5 μM). Astrocytes were 
voltage-clamped at –80 mV with a 
KMeSbased internal solution. (B) Glutamate 
transporter currents evoked in Purkinje 
neurons through photolysis of MNI-D-
aspartate (500 μM), in the absence and 
presence of TBOA (200 μM). Cesium nitrate 
(CsNO3)-based internal solution. (C) 
Glutamate transporter currents were not 
observed in hippocampal CA1 pyramidal 
neurons. (C1) A small inward current was 
evoked in a rat hippocampal CA1 pyramidal neuron in response to photolysis of MNI-D-aspartate (500 μM). 
The inward current was slightly larger in the presence than in the absence of MNI-D-aspartate; however, this 
response was not inhibited by TBOA (200 μM). (C2) Photolysis-evoked currents from CA1 pyramidal neurons 
in slices from wild-type (EAAC1+/+) and EAAC1 deficient (EAAC1-/-) mice, showing no significantly larger 
current in wild-type mice. Recordings were made in the presence of TTX (1 μM), R,S-CPP (10 μM), MK-801 
(50 μM), 5,7-Dichlorolkynurenic acid (20-100 μM), NBQX (10 μM) and SR95531 
(5 μM). Pyramidal neurons were voltage-clamped at -65 mV with a potassium thiocyanate-based internal 
solution. 
 
D-Aspartate uptake in nerve 
terminals in rat hippocampal slices 
To increase the sensitivity of detection, 
we attempted to visualize EAAC1 
activity in spines using 
immunocytochemistry. D-aspartate was 
chosen as a transporter substrate 
because this molecule is poorly 
metabolized in brain tissue (Davies and 
Johnston, 1976; Takagaki, 1978). 
Hippocampal slices were incubated 
with D-aspartate, fixed, embedded, cut, 
immunolabeled and studied electron 
microscopically in the stratum radiatum  
 
Figure 15.  Glutamate uptake in spines is relatively low, as demonstrated by D-Aspartate uptake and 
immunocreactivity. Hippocampal slices form adult rat (9 weeks old) were incubated in D-aspartate (50 M, 3 
min), fixed (1 % formaldehyde and 2.5 % glutaraldehyde) and immunogold labeled with antibodies to 
glutaraldehyde-fixed D-aspartate. Labeling shows accumulation of D aspartate in.nerve terminals (t) - (there is a 
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high number of black uniformly sized dots representing gold-particles over the terminal). Glia (not shown) were 
also heavily labeled. Dendrites and dendritic spines (s) were virtually unlabeled. Note that there are no gold-
particles over the spine (s). Arrowheads indicate the location of a synaptic cleft. Scale bar, 300 nm. 
 
of area CA1. D-aspartate immunoreactivity was observed in synaptic terminals (Fig. 15) and 
astroglia (not shown). Despite heavy labeling of these structures, no labeling of spines was 
observed (Fig. 15). Hippocampal slices incubated without D-aspartate had very little 
immunoreactivity, while slices incubated with D-aspartate in combination with an uptake 
inhibitor (L-glutamate or dihydrokainate) were weakly positive (data not shown; see Furness 
et al., 2008). Thus, the uptake activity in spines is negligible compared to that present in 
other synaptic compartments.  
 
 
DISCUSSION 
EAAC1 has been intensely studied, but experimental data has been interpreted quite 
differently; in part because quantitative data on EAAC1 protein levels have been lacking.  
 
EAAC1 is exclusively expressed by neurons throughout the CNS 
In agreement with other reports on EAAC1 distribution (for review see: Danbolt, 2001), we 
show that EAAC1 is present in the cell bodies and dendrites of most, if not all, neurons in the 
forebrain. Also in agreement with many (Kanai and Hediger, 1992; Rothstein et al., 1994; 
Torp et al., 1997; Berger and Hediger, 1998; Coco et al., 1997; Shashidharan et al., 1997; 
Plachez et al., 2000; Holmseth et al., 2005), but not all (e.g. Conti et al., 1998; Kugler and 
Schmitt, 1999), we do not find evidence for expression in astrocytes and oligodendrocytes.  
 
Is EAAC1 in terminals? 
Another unresolved issue is the reported pre-synaptic expression of EAAC1. Rothstein and 
co-workers (Rothstein et al., 1994) did not find EAAC1 in glutamatergic terminals, but noted 
that GABAergic terminals in the deep cerebellar nuclei were labeled. Other studies (He et al., 
2000; He et al., 2001) reported that EAAC1 is present in both GABAergic and glutamatergic 
terminals, and found about 10 % of the labeling in the latter. However, these investigators did 
not have access to tissue from the EAAC1-deficient mice to verify the labeling specificity, 
and their conclusions are at variance with other reports (e.g. Shashidharan et al., 1997; Conti 
et al., 1998; Holmseth et al., 2005) as well as with our data (Fig. 11). Further, in agreement 
with Rothstein (1994) we find no glutamate uptake activity in glutamatergic terminals in 
GLT1-deficient mice (Furness et al., 2008). In conclusion, we are unable to support the 
notion that there are functionally relevant levels of EAAC1 in glutamatergic terminals. 
 In GABAergic terminals, however, the situation is more complex. A study based on 
antisense knockdown of EAAC1 concluded that EAAC1 is important for GABA synthesis in 
GABAergic terminals (Sepkuty et al., 2002). It can be argued that antisense probes may have 
unrecognized effects, but there is other functional evidence for glutamate uptake into 
GABAergic terminals (Mathews and Diamond, 2003; Stafford et al., 2010). The latter studies 
show that raising the extracellular glutamate levels, increases mIPSC amplitudes possibly 
because EAAC1-mediated glutamate uptake in GABAergic terminals provides glutamate for 
GABA synthesis increasing GABA levels. However, Stafford and co-workers (2010), in 
agreement with our data, failed to detect EAAC1 protein in terminals directly. In stead, they 
incubated slices in D-aspartate (250 M; 30 min) and double-labeled these with antibodies to 
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D-aspartate and GAD. By this method they showed that D-aspartate can be taken up by 
GABAergic terminals. This is in principle a sensitive technique because each transporter can 
transport a huge number of D-aspartate molecules in 30 minutes. However, the D-aspartate 
concentration used was 30 times higher than Km (Km for D-aspartate is 7.5 M; Kanai and 
Hediger, 1992). This weakens the argument because maximum EAAC1 mediated uptake 
should be observed at lower concentrations. Thus, it can be argued that the observed uptake 
is due to other transporters. Nevertheless, the authors conclude that EAAC1 is likely there, at 
densities below the threshold for direct detection. The limit for direct detection with 
antibodies is unknown, but a fair guess with our antibodies is that the limit is at around 10 % 
of the average density observed in hippocampal spines. If so, the possibility exists that up to 
dozen EAAC1 molecules in each GABAergic terminal may have evaded our detection, but 
this is probably not enough EAAC1 molecules to account for the observed increased mIPSC 
amplitudes.  
 
Cell surface expression of EAAC1 
In order for transporters to participate in glutamate clearance, they must be localized to the 
plasma membrane. GLT1, GLAST (Lehre and Danbolt, 1998) and EAAT4 (Dehnes et al., 
1998) are highly enriched at the cell surface, and transporter-mediated currents can be 
recorded from astrocytes (Bergles and Jahr, 1997; Huang et al., 2004) and Purkinje cells 
(Otis et al., 1997) in response to application of substrates, supporting a role for these 
transporters in glutamate clearance. In contrast, EAAC1 immunoreactivity was 
predominantly intracellular, where it was often associated with vesicle-like structures. It 
could be that proteins anchoring EAAC1 at the surface mask the epitope making EAAC1 at 
the cell surface invisible. This is, however, unlikely because similar results were obtained by 
an antibody to another EAAC1 region (Shashidharan et al., 1997) and because EAAC1 was 
readily detected in the brush border in the kidney. Further, cell culture studies show that only 
20-30% of EAAC1 is localized at the plasma membrane (Fournier et al., 2004; Sheldon et al., 
2006), and we were unable to record EAAC1-mediated transporter currents from neurons 
(see also Bergles and Jahr, 1998).  
 
The contribution of EAAC1 to synaptic glutamate clearance 
As shown here (Table 3), the mean EAAC1 density (in hippocampus of young adult rats) was 
approximately 90 transporters per square micrometer of dendritic membrane, provided all 
EAAC1 is inserted into the membrane, and about 130 molecules per synapse. As several 
thousand molecules of glutamate are released from each vesicle, it appears unlikely that there 
are enough EAAC1 transporters to have an appreciable effect on glutamate clearance in the 
brain, in agreement with our electrophysiological results, i.e. the lack of detectable glutamate 
uptake currents in hippocampal pyramidal cells and the lack of significant differences 
between such currents in pyramidal neurons from wild-type and EAAC1-knockout mice. 
Further, the low glutamate uptake activity in the GLT1-deficient mice (Fig. 4) and the low 
uptake activity in spines (Fig. 15; see also Furness et al., 2008) also point to a negligible 
contribution from EAAC1. Our findings are, however, at variance with reports based on 
antisense knockdown of transporters (Rothstein et al., 1996). A possible explanation for this 
is unrecognized side effects of the antisense probes causing an overestimation of the 
importance of EAAC1.  
 The results presented here suggest that GLT1 represents about 80 % of all glutamate 
transporter proteins in the young adult hippocampus, with GLAST comprising most of the 
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remaining 20 %, and EAAC1 representing only about 1 %. Because GLAST and EAAC1 are 
about 6 and 1.5 times slower than GLT1 (Grewer and Rauen, 2005), respectively, it follows 
that the effective contribution to uptake activity is dominated by GLT1 (> 95 %) in 
agreement with previous data (Haugeto et al., 1996; Tanaka et al., 1997).  
 
Physiological roles of EAAC1 in the brain 
EAAC1 appears to be the only glutamate transporter expressed by most mature neurons. As it 
also transports cysteine, it seems likely that EAAC1 does serve metabolic roles as suggested 
(Aoyama et al., 2006). As explained above, EAAC1 is not likely to contribute to the 
maintenance of low resting levels of glutamate.  
 However, in the absence of an EAAC1 selective antagonist, it is difficult to assess 
more sophisticated functions of this transporter in the brain. Scimemi and co-workers (2009) 
addressed this question and described functional differences in hippocampal slices from wild-
type and EAAC1-knockout mice. They suggest that EAAC1 buffers glutamate released 
during synaptic events and prolongs the time course of its clearance by astrocytes. Without 
significantly altering activation of receptors in the synaptic cleft, EAAC1 reduces recruitment 
of perisynaptic/extrasynaptic NR2B-containing NMDARs, thereby facilitating induction of 
long-term potentiation by short bursts of high-frequency stimulation. This is an unusually 
extensive and impressive study. As far as we can see, they have taken into account all factors 
known to be relevant. However, their own 3D Monte Carlo modeling only matches their 
experimental data if EAAC1 is less efficient than GLT1, and if EAAC1 is present in numbers 
that are much higher than those we report here. It therefore seems likely that the functional 
differences between wild-type and EAAC1-knockout mice (Scimemi et al., 2009) are caused 
by as yet unidentified downstream consequences of the loss of EAAC1, possibly in 
combination with other factors such as the trauma induced by the slicing of brain tissue or by 
the subsequent in vitro treatment. After all, tissue ultrastructure, such as astrocytic coverage 
of synapses, is modulated by neuronal activity (e.g. Genoud et al., 2006), and the 
ultrastructure of hippocampal slice preparations is affected by the method of preparation and 
is quite different from that of hippocampus fixed in vivo by cardiac perfusion (e.g. Fiala et 
al., 2003). Although Scimemi and co-workers (2009) have considered these factors and also 
have considered impaired glutathione synthesis (Aoyama et al., 2006), there may yet be 
unidentified differences between wild-type and EAAC1-deficient mice.  
 
Conclusions 
EAAC1 is present in cell bodies and dendrites of most, if not all, neurons. It was not detected 
in terminals, neither glutamatergic nor GABAergic. Further, EAAC1 was not detected in 
astrocytes, oligodendrocytes or endothelial cells. The concentration of EAAC1 in the young 
adult hippocampus is two orders of magnitude lower than that of GLT1. The localization and 
the low expression levels argue against a role in glutamate clearance and buffering. EAAC1 
is more likely to play metabolic roles considering that it can transport both glutamate and 
cysteine, and that it is the only glutamate transporter expressed by most neurons. 
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